# EDGAR Filing Document

**Accession Number:** 0000889971
**File Stem:** 0001437749-26-015594
**Filing Date:** 2026-5
**Character Count:** 224396
**Document Hash:** 8df5e9382e1ce87c1ad73857ca68ad4c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-015594.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001437749-26-015594

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 100

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIGHTPATH TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0000889971
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 860708398
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-27548
- **FILM NUMBER:** 26953758

**BUSINESS ADDRESS:**
- **STREET 1:** 2603 CHALLENGER TECH CT
- **STREET 2:** STE 100
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32826-2716
- **BUSINESS PHONE:** 4073824003

**MAIL ADDRESS:**
- **STREET 1:** 2603 CHALLENGER TECH CT
- **STREET 2:** STE 100
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32826-2716

?xml version='1.0' encoding='ASCII'? lpth20260331_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended <u>March 31, 2026</u>

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ____________

**Commission file number 000-27548**

**LIGHTPATH TECHNOLOGIES, INC.**

------

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **86-0708398** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**2603 Challenger Tech Ct. Suite 100**

<u>**Orlando, Florida 32826**</u>

(Address of principal executive offices)

(ZIP Code)

<u>**(407) 382-4003**</u>

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| <br>Class A Common<br> Stock, par value $0.01<br>| LPTH | The Nasdaq Stock Market, LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

62,789,407 shares of Class A common stock, $0.01 par value, outstanding as of May 4, 2026.

------

[**Table of Contents**](#toc)

**LIGHTPATH TECHNOLOGIES, INC.**

**Form 10-Q**

**Index**

---

| | | |
|:---|:---|:---|
| **Item** |  | **Page** |
| [Cautionary Note Concerning Forward-Looking Statements](#cautionary) | [Cautionary Note Concerning Forward-Looking Statements](#cautionary) | [3](#cautionary) |
| [**Part I**](#part1) | [**Financial Information**](#part1) |  |
| [Item 1](#finstmts) | [Financial Statements](#finstmts) | [4](#finstmts) |
|  | [Unaudited Condensed Consolidated Balance Sheets](#balancesheets) | [4](#balancesheets) |
|  | [Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)](#income) | [5](#income) |
|  | [Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity](#equity) | [6](#equity) |
|  | [Unaudited Condensed Consolidated Statements of Cash Flows](#cashflows) | [7](#cashflows) |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#notes) | [8](#notes) |
| [Item 2](#mda) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#mda) | [27](#mda) |
|  | [Results of Operations](#results) | [30](#results) |
|  | [Liquidity and Capital Resources](#liquidity) | [32](#liquidity) |
|  | [Critical Accounting Policies and Estimates](#critical) | [33](#critical) |
|  | [How We Operate](#howweoperate) | [33](#howweoperate) |
|  | [Non-GAAP Financial Measures](#nongaap) | [36](#nongaap) |
| [Item 3](#quant) | [Quantitative and Qualitative Disclosures about Market Risk](#quant) | [37](#quant) |
| [Item 4](#controls) | [Controls and Procedures](#controls) | [37](#controls) |
| [**Part II**](#part2) | [**Other Information**](#part2) |  |
| [Item 1](#legal) | [Legal Proceedings](#legal) | [38](#legal) |
| [Item 1A](#risk) | [Risk Factors](#risk) | [38](#risk) |
| [Item 2](#unregistered) | [Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](#unregistered) | [38](#unregistered) |
| [Item 3](#defaults) | [Defaults Upon Senior Securities](#defaults) | [38](#defaults) |
| [Item 4](#mine) | [Mine Safety Disclosures](#mine) | [38](#mine) |
| [Item 5](#otherinfo) | [Other Information](#otherinfo) | [38](#otherinfo) |
| [Item 6](#exhibits) | [Exhibits](#exhibits) | [39](#exhibits) |
| [**Signatures**](#signatures) |  | [40](#signatures) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS**

*Certain statements and information in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the* "*Quarterly Report*"*) may constitute* "*forward-looking statements*" *within the meaning of Section 27A of the Securities Act of 1933, as amended (the* "*Securities Act*"*), Section 21E of the Securities Exchange Act of 1934, as amended (the* "*Exchange Act*"*), and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as* "*may,*" "*will,*" "*should,*" "*expect,*" "*plan,*" "*anticipate,*" "*believe,*" "*estimate,*" "*predict,*" "*potential,*" *or* "*continue,*" *or other comparable terminology. These forward-looking statements include, without limitation, statements regarding:* 

● *our intentions regarding the use of our earnings generated by our subsidiaries;* 

● *our belief that our acquisitions will align with our overall strategy;* 

● *our expectations regarding market growth potential and market conditions, including in international markets;* 

● *our belief that our product groups are aligned with our strategic direction, as well as our ability to focus on higher margin products;* 

● *our ability to remain competitive through differentiating technology;* 

● *the impact of trade actions on our operations and financial condition;* 

● *our ability to successfully create a sustainable annuity revenue stream;* 

● *our expectation that our existing contracts will be renewed in future quarters;* 

● *our expectations regarding the performance and demand of our products;* 

● *our anticipated timing for our ability to deliver hardware during fiscal 2026; and* 

● *any other statements regarding our plans, opinions, expectations, beliefs, objectives, assumptions or projections regarding future events or future results and underlying assumptions and other statements, which are not statements of historical facts.* 

*These forward-looking statements are based largely on our current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond our control. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting us will be those that we anticipate. These statements are subject to many risks, uncertainties, and other important factors that could cause actual future results to differ materially from those expressed in the forward-looking statements including, but not limited to, the impact of tariffs and other governmental trade restrictions, our ability to obtain needed raw materials and components from our suppliers; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; geopolitical tensions, the Russian-Ukraine conflict, and the Hamas/Israel war; the effects of steps that we could take to reduce operating costs; rising inflation and increased interest rates, which diminish capital market cash flow and borrowing power; our inability to sustain profitable sales growth, convert inventory to cash, or reduce our costs to maintain competitive prices for our products; circumstances or developments that may make us unable to implement or realize the anticipated benefits, or that may increase the costs, of our current and planned business initiatives; and those factors detailed by us in our public filings with the Securities and Exchange Commission (the* "*SEC*"*), including in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2025. In light of these risks and uncertainties, all of the forward-looking statements made herein are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized. We undertake no obligation to update or revise any of the forward-looking statements contained herein.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**<u>PART I. FINANCIAL INFORMATION</u>**

**Item 1. Financial Statements**

**LIGHTPATH TECHNOLOGIES, INC.**

**Condensed Consolidated Balance Sheets**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***June 30,*** |
|  | ***2026*** | ***2025*** |
| **Assets** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $55235181 | $4877036 |
| Trade accounts receivable, net of allowance of $49,017 and $24,495 | 10797645 | 9455310 |
| Inventories, net | 13344705 | 12858838 |
| Prepaid expenses and deposits | 3440598 | 1142661 |
| Other current assets | 185503 | 40150 |
| Total current assets | 83003632 | 28373995 |
| Property and equipment, net | 15828239 | 15864061 |
| Operating lease right-of-use assets | 8406283 | 7429378 |
| Intangible assets, net | 17589628 | 15987923 |
| Goodwill | 19315177 | 13753921 |
| Deferred tax assets, net | 22233 | 22571 |
| Other assets | 99987 | 73917 |
| Total assets | $144265179 | $81505766 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $6030975 | $7421430 |
| Accrued liabilities | 10813017 | 5686396 |
| Accrued payroll and benefits | 3125747 | 2359152 |
| Operating lease liabilities, current | 1177423 | 1254062 |
| Loans payable, current portion | 113085 | 172567 |
| Finance lease obligation, current portion | 271015 | 206518 |
| Total current liabilities | 21531262 | 17100125 |
| Deferred tax liabilities, net | 88099 | 152760 |
| Accrued liabilities, noncurrent |  | 823000 |
| Finance lease obligation, less current portion | 460316 | 421363 |
| Operating lease liabilities, noncurrent | 9197980 | 8326250 |
| Loans payable, less current portion | 103661 | 4804990 |
| Total liabilities | 31381318 | 31628488 |
| Commitments and Contingencies |  |  |
| Series G Convertible Preferred Stock; $0.01 par value; 44,000 shares authorized; 17,346 and 24,956 shares issued and outstanding | $23794184 | $34232510 |
| Stockholders' equity: |  |  |
| Preferred stock: Series D, $0.01 par value, voting; 500,000 shares authorized; none issued and outstanding |  |  |
| Common stock: Class A, $0.01 par value, voting; 94,500,000 shares authorized; 61,207,012 and 42,949,307 shares issued and outstanding | 612070 | 429493 |
| Additional paid-in capital | 334313395 | 244953346 |
| Accumulated other comprehensive income | 1285667 | 978686 |
| Accumulated deficit | (247121455) | (230716757) |
| Total stockholders' equity | 89089677 | 15644768 |
| Total liabilities, convertible preferred stock and stockholders' equity | $144265179 | $81505766 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**LIGHTPATH TECHNOLOGIES, INC.**

**Condensed Consolidated Statements of Comprehensive Income (Loss)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Revenue, net | $19149814 | $9167627 | $50559747 | $24992837 |
| Cost of sales | 12193531 | 6503526 | 33100562 | 17553476 |
| Gross profit | 6956283 | 2664101 | 17459185 | 7439361 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 6296286 | 4448359 | 16539617 | 11075005 |
| New product development | 1041794 | 757938 | 2658051 | 1998775 |
| Amortization of intangible assets | 477245 | 779025 | 1378295 | 1469512 |
| Change in fair value of acquisition earnout liabilities | 3393000 | 130445 | 12234529 | 130445 |
| Loss on disposal of property and equipment |  | 2068 | 4016 | 80505 |
| Total operating expenses | 11208325 | 6117835 | 32814508 | 14754242 |
| Operating loss | (4252042) | (3453734) | (15355323) | (7314881) |
| Other income (expense): |  |  |  |  |
| Interest income (expense), net | 271641 | (486833) | (282235) | (805246) |
| Loss on extinguishment of debt |  | (418502) | (506280) | (418502) |
| Change in fair value of warrant liability |  | 870554 |  | 870554 |
| Other expense (income), net | (34496) | 6086 | (57644) | 11065 |
| Total other income (expense) | 237145 | (28695) | (846159) | (342129) |
| Loss before income taxes | (4014897) | (3482429) | (16201482) | (7657010) |
| Income tax provision | 91390 | 100031 | 203216 | 160192 |
| Net loss | $(4106287) | $(3582460) | $(16404698) | $(7817202) |
| Foreign currency translation adjustment | 1739 | 120572 | 306981 | (58869) |
| Comprehensive loss | $(4104548) | $(3461888) | $(16097717) | $(7876071) |
| Loss per common share (basic) | $(0.07) | $(0.09) | $(0.33) | $(0.19) |
| Number of shares used in per share calculation (basic) | 58628741 | 41363643 | 49572872 | 40209657 |
| Loss per common share (diluted) | $(0.07) | $(0.09) | $(0.33) | $(0.19) |
| Number of shares used in per share calculation (diluted) | 58628741 | 41363643 | 49572872 | 40209657 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**LIGHTPATH TECHNOLOGIES, INC.**

**Condensed Consolidated Statements of Changes in Stockholders' Equity**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Temporary Equity*** | ***Temporary Equity*** |  |  |  | ***Accumulated*** |  |  |
|  | ***Series G Convertible*** | ***Series G Convertible*** | ***Class A*** | ***Class A*** | ***Additional*** | ***Other*** |  | ***Total*** |
|  | ***Preferred Stock*** | ***Preferred Stock*** | ***Common Stock*** | ***Common Stock*** | ***Paid-in*** | ***Comprehensive*** | ***Accumulated*** | ***Stockholders'*** |
|  | ***Shares*** | ***Amount*** | ***Shares*** | ***Amount*** | ***Capital*** | ***Income*** | ***Deficit*** | ***Equity*** |
| **Balances at June 30, 2025** | **24956** | $**34232510** | **42949307** | $**429493** | $**244953346** | $**978686** | $**(230716757)** | $**15644768** |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| Exercise of stock options, RSUs & RSAs, net |  |  | 8583 | 86 | (86) |  |  |  |
| Issuance of common stock under private equity placement |  |  | 1600000 | 16000 | 7878045 |  |  | 7894045 |
| Issuance of common stock for acquisition of Visimid |  |  | 112323 | 1123 | 348877 |  |  | 350000 |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 349624 |  |  | 349624 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | 92383 |  | 92383 |
| Net loss | *—* |  | *—* |  |  |  | (2893002) | (2893002) |
| **Balances at September 30, 2025** | **24956** | $**34232510** | **44670213** | $**446702** | $**253529806** | $**1071069** | $**(233609759)** | $**21437818** |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| Exercise of stock options, RSUs & RSAs, net |  |  | 120234 | 1203 | (1203) |  |  |  |
| Exercise of warrants |  |  | 739730 | 7397 | (7397) |  |  |  |
| Issuance of common stock under public equity placement |  |  | 8912500 | 89125 | 65251709 |  |  | 65340834 |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 348986 |  |  | 348986 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | 212859 |  | 212859 |
| Net loss | *—* |  | *—* |  |  |  | (9405409) | (9405409) |
| **Balances at December 31, 2025** | **24956** | $**34232510** | **54442677** | $**544427** | $**319121901** | $**1283928** | $**(243015168)** | $**77935088** |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| Employee Stock Purchase Plan |  |  | 2302 | 23 | 24839 |  |  | 24862 |
| Exercise of stock options, RSUs & RSAs, net |  |  | 112723 | 1127 | 11376 |  |  | 12503 |
| Exercise of warrants |  |  | 2728968 | 27290 | (27290) |  |  |  |
| &nbsp;&nbsp;&nbsp; Fees for issuance of common stock under public equity placement | *—* |  | *—* |  | (98293) |  |  | (98293) |
| Issuance of common stock for acquisition of Amorphous |  |  | 83518 | 835 | 1026245 |  |  | 1027080 |
| Issuance of common stock for acquisition of G5 |  |  | 297445 | 2974 | 3146968 |  |  | 3149942 |
| Conversion of Series G Preferred to Common | (7610) | (10438326) | 3539379 | 35394 | 10402932 |  |  | 10438326 |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 704717 |  |  | 704717 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | 1739 |  | 1739 |
| Net loss | *—* |  | *—* |  |  |  | (4106287) | (4106287) |
| **Balances at March 31, 2026** | **17346** | $**23794184** | **61207012** | $**612070** | $**334313395** | $**1285667** | $**(247121455)** | $**89089677** |
| **Balances at June 30, 2024** |  | $— | **39254643** | $**392546** | $**245140758** | $**509936** | $**(215843575)** | $**30199665** |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| Employee Stock Purchase Plan |  |  | 8232 | 82 | 10290 |  |  | 10372 |
| Exercise of Stock Options, RSUs & RSAs, net |  |  | 70309 | 703 | (703) |  |  |  |
| Issuance of common stock for acquisition of Visimid |  |  | 279553 | 2796 | 318562 |  |  | 321358 |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 264475 |  |  | 264475 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | 271594 |  | 271594 |
| Net loss | *—* |  | *—* |  |  |  | (1622745) | (1622745) |
| **Balances at September 30, 2024** |  | $— | **39612737** | $**396127** | $**245733382** | $**781530** | $**(217466320)** | $**29444719** |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| Exercise of Stock Options, RSUs & RSAs, net |  |  | 229097 | 2291 | (2291) |  |  |  |
| Shares issued as compensation |  |  | 49000 | 490 | 89180 |  |  | 89670 |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 231581 |  |  | 231581 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | (451035) |  | (451035) |
| Net loss | *—* |  | *—* |  |  |  | (2611997) | (2611997) |
| **Balances at December 31, 2024** |  | $— | **39890834** | $**398908** | $**246051852** | $**330495** | $**(220078317)** | $**26702938** |
| Issuance of preferred stock under private equity placement, net of fees | 24956 | 19648488 | *—* | *—* |  |  |  |  |
| Issuance of common stock for: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Employee Stock Purchase Plan |  |  | 1137 | 11 | 4002 |  |  | 4013 |
| &nbsp;&nbsp;&nbsp; Exercise of Stock Options, RSUs & RSAs, net |  |  | 238641 | 2387 | 788 |  |  | 3175 |
| &nbsp;&nbsp;&nbsp; Issuance of common stock for acquisition of Visimid |  |  | 102700 | 1027 | 391561 |  |  | 392588 |
| &nbsp;&nbsp;&nbsp; Issuance of common stock for acquisition of G5 |  |  | 1972501 | 19725 | 4852343 |  |  | 4872068 |
| &nbsp;&nbsp;&nbsp; Issuance of common stock under private equity placement, net of fees | *—* | *—* | 687750 | 6878 | 1584014 |  |  | 1590892 |
| &nbsp;&nbsp;&nbsp; Issuance of warrants under private placement, net of fees | *—* |  | *—* |  | 177445 |  |  | 177445 |
| Preferred cumulative dividends plus accretion | *—* | 14751134 | *—* |  | (14751134) |  |  | (14751134) |
| Stock-based compensation on stock options, RSUs & RSAs | *—* |  | *—* |  | 194303 |  |  | 194303 |
| Foreign currency translation adjustment | *—* |  | *—* |  |  | 120572 |  | 120572 |
| Net loss | *—* |  | *—* |  |  |  | (3582460) | (3582460) |
| **Balances at March 31, 2025** | **24956** | $**34399622** | **42893563** | $**428936** | $**238505174** | $**451067** | $**(223660777)** | $**15724400** |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**LIGHTPATH TECHNOLOGIES, INC.**

**Condensed Consolidated Statements of Cash Flows**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| Cash flows from operating activities: |  |  |
| Net loss | $(16404698) | $(7817202) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Depreciation and amortization | 3717691 | 3356752 |
| Interest from amortization of loan issuance costs | 90124 | 161905 |
| Amortization of fair value of loan | 90321 |  |
| Loss on extinguishment of debt | 506280 | 418502 |
| Change in fair value of warrant liability |  | (870554) |
| Change in fair value of acquisition earnout liabilities | 12234529 | 130445 |
| Earnout payment for acquisition of G5, net of financing portion | (3813587) |  |
| Loss on disposal of property and equipment | 4016 | 80505 |
| Stock-based compensation on stock options, RSUs & RSAs, net | 1261577 | 745155 |
| Provision for credit losses | (26034) | (3014) |
| Change in operating lease assets and liabilities | (181814) | (91582) |
| Inventory write-offs to allowance | 215129 | 135625 |
| Deferred taxes | (64323) | (2368) |
| Changes in operating assets and liabilities, net of acquisitions: |  |  |
| Trade accounts receivable | (1200965) | (822043) |
| Other current assets | (145353) | 73362 |
| Inventories | (247597) | (1206340) |
| Prepaid expenses and deposits | (2182257) | (360439) |
| Accounts payable and accrued liabilities | 1030382 | 389844 |
| Net cash used in operating activities | (5116579) | (5681447) |
| Cash flows from investing activities: |  |  |
| Purchase of property and equipment | (1844395) | (580726) |
| Proceeds from sale of equipment |  | 10648 |
| Acquisition of Amorphous | (7000111) |  |
| Acquisition of G5 |  | (20250011) |
| Net cash used in investing activities | (8844506) | (20820089) |
| Cash flows from financing activities: |  |  |
| Proceeds from exercise of stock options | 12503 | 3175 |
| Proceeds from sale of common stock from Employee Stock Purchase Plan | 24862 | 14385 |
| &nbsp;&nbsp;&nbsp; Proceeds from issuance of common stock under public equity placement, net of fees | 65242541 |  |
| Proceeds from issuance of common stock under private equity placement, net of fees | 7894045 | 437725 |
| Proceeds from issuance of preferred stock under private equity placement, net of fees |  | 18842138 |
| Proceeds from issuance of warrants under private equity placement, net of fees |  | 4620561 |
| Earnout payment for acquisition of G5, net of operating portion | (3536471) |  |
| Deferred payment for acquisition of Visimid |  | (125000) |
| Borrowings on loans payable |  | 6659596 |
| Loan issuance costs |  | (597465) |
| Payments on loans payable | (5442930) | (149118) |
| Repayment of finance lease obligations | (168089) | (133711) |
| Net cash provided by financing activities | 64026461 | 29572286 |
| Effect of exchange rate on cash and cash equivalents | 292769 | (72133) |
| Change in cash and cash equivalents | 50358145 | 2998617 |
| Cash and cash equivalents, beginning of period | 4877036 | 3480268 |
| Cash and cash equivalents, end of period | $55235181 | $6478885 |
| Supplemental disclosure of cash flow information: |  |  |
| Interest paid in cash | $390457 | $66136 |
| Income taxes paid | $194527 | $118016 |
| Supplemental disclosure of non-cash investing & financing activities: |  |  |
| &nbsp;&nbsp;&nbsp; Purchase of equipment through finance lease arrangements | $275471 | $93048 |
| Operating right-of-use assets acquired in exchange for operating lease liabilities | $1956911 | $— |
| Issuance of common stock for acquisition of Visimid | $350000 | $713946 |
| Issuance of common stock for acquisition of G5, including earnouts | $3149942 | $4872068 |
| &nbsp;&nbsp;&nbsp; Issuance of common stock for acquisition of AML, including earnouts | $1027080 | $— |
| Accrual of earnout consideration for acquisition of G5 | $— | $3536471 |
| &nbsp;&nbsp;&nbsp; Accrual of earnout consideration for acquisition of AML | $1780000 | $— |
| Extinguishment of debt in exchange for common stock, preferred stock, warrants and a note | $— | $3057110 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

[**Table of Contents**](#toc)

**LIGHTPATH TECHNOLOGIES, INC.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

***1.* Basis of Presentation**

References in this document to the "Company," "LightPath," "we," "us," or "our" are intended to mean LightPath Technologies, Inc., individually, or as the context requires, collectively with its subsidiaries on a consolidated basis.

These unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the requirements of Article *8* of Regulation S-*X* promulgated under the Exchange Act and, therefore, do *not* include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America ("GAAP"). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with our Consolidated Financial Statements and related notes, included in our Annual Report on Form *10*-K for the fiscal year ended *June 30, 2025*, filed with the SEC. Unless otherwise stated, references to particular years or quarters refer to our fiscal years ended *June 30* and the associated quarters of those fiscal years.

These Condensed Consolidated Financial Statements are unaudited, but include all adjustments, including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly our financial position, results of operations and cash flows for the interim periods presented. The Condensed Consolidated Balance Sheet as of *June 30, 2025* has been derived from the audited financial statements at that date but does *not* include all of the information and notes required by generally accepted accounting principles for complete financial statements. Results of operations for interim periods are *not* necessarily indicative of the results that *may* be expected for the year as a whole. The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

***2.* Significant Accounting Policies**

Our significant accounting policies are provided in Note *2, Summary of Significant Accounting Policies*, in the Consolidated Financial Statements in our Annual Report on Form *10*-K for the fiscal year ended *June 30, 2025*. There have been *no* material changes to our significant accounting policies during the *nine* months ended *March 31, 2026*, from those disclosed in our Annual Report on Form *10*-K for the fiscal year ended *June 30, 2025*.

*Use of Estimates*

Management makes estimates and assumptions during the preparation of our unaudited Condensed Consolidated Financial Statements that affect amounts reported in the unaudited Condensed Consolidated Financial Statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes available, which, in turn, could impact the amounts reported and disclosed herein.

*Fair Value of Financial Instruments*

We account for financial instruments in accordance with the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification Topic *820,* "*Fair Value Measurements and Disclosures*" ("ASC *820"*), which provides a framework for measuring fair value and disclosure requirements for fair value measurements of assets and liabilities. ASC *820* defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC *820* also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes *three* levels of inputs that *may* be used to measure fair value:

Level *1* - Quoted prices in active markets for identical assets or liabilities.

Level *2* - Inputs other than quoted prices included within Level *1* that are either directly or indirectly observable.

Level *3* - Unobservable inputs that are supported by little or *no* market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management.

We valued certain financial instruments issued in connection with the acquisition of *G5* Infrared (as defined below) using Level *3* fair value measurements, including warrants, Series G Convertible Preferred Stock (as defined below) and the Acquisition Notes (as defined below).

In connection with the acquisition of *G5* Infrared, the Company also valued the earnout liability and the intangible assets acquired using Level *3* fair value methods. See Note *4, Acquisition of *G5* Infrared*, to these unaudited Condensed Consolidated Financial Statements for additional information.

Other than as disclosed above, the Company does *not* have any other financial or non-financial assets or liabilities that would be characterized as Level *1,* Level *2* or Level *3* instruments.

***3.* Acquisition of Amorphous Materials**

On *January 20, 2026,* we entered into an Asset Purchase Agreement (the "Asset Purchase Agreement"), by and among the Company, Amorphous Materials, LLC ("AML"), a Delaware limited liability company and wholly-owned subsidiary of the Company ("Buyer"), Amorphous Materials, Inc., a Texas corporation ("Seller") and other parties thereto, pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, Buyer agreed to acquire substantially all of the assets (collectively, the "Assets") and assume and acquire certain of the rights and liabilities of Seller (collectively, the "Liabilities" and such acquisition of Assets and assumption of the Liabilities together, the "Transaction") relating to Seller's business of compounding and melting a broad range of Chalcogenide glasses for *third*-party manufacturers. The Transaction closed on *January 21, 2026 (*the "AML Acquisition Date").

Aggregate consideration payable by the Company to Seller under the Asset Purchase Agreement in connection with the Transaction will *not* exceed $10.0 million and consists of (i) a cash payment of $7.0 million that was paid at closing (the "Cash Consideration") and (ii) contingent consideration that will *not* exceed $3.0 million (the "Contingent Consideration"). The Contingent Consideration, if earned, is payable in shares of the Company's Class A common stock, $0.01 par value, ("Common Stock"), to be issued in up to *six* tranches of $500,000 each divided by the LPTH Stock Price (as calculated pursuant to the Asset Purchase Agreement) upon the achievement of certain milestones set forth in the Asset Purchase Agreement (each, a "Contingent Consideration Payment").

We accounted for the acquisition of AML using the acquisition method of accounting, which required us to measure identifiable assets acquired and liabilities assumed in the acquiree at their fair values as of the AML Acquisition Date, with the excess of the consideration transferred over those fair values recorded as goodwill. We are in the process of obtaining *third*-party valuations of certain intangible assets; thus, the provisional measurements of intangible assets, goodwill and deferred income tax assets are subject to change.

As of *January 20, 2026,* Seller satisfied the *first* milestone contemplated by the Contingent Consideration Payments and received an aggregate of 39,897 shares of Common Stock (or approximately $544,000 at fair value, determined by multiplying the number of shares issued by the fair value of the Common Stock on the AML Acquisition Date). On *March 10, 2026,* following the achievement of the *second* milestone, an additional 43,621 shares of Common Stock were issued (or approximately $482,000 at fair value as of the issuance date). The remaining estimated potential earnout has been accrued based on a preliminary *third*-party valuation and is included in Accrued liabilities the accompanying unaudited Condensed Consolidated Balance Sheet as of *March 31, 2026.*

As of the AML Acquisition Date, the preliminary fair value of the aggregate consideration was approximately $9.2 million which consisted of (i) the Cash Consideration, (ii) 39,897 shares of Common Stock (or approximately $544,000 at fair value, determined by multiplying the number of shares issued by $13.64 per share, which was the closing price on the AML Acquisition Date), and (iii) potential earnout consideration subject to achievement of *five* additional technical milestones, as defined in the Asset Purchase Agreement. As of the AML Acquisition Date, the fair value of consideration transferred consisted of the following:

---

| | |
|:---|:---|
|  | ***January 21,*** |
| **Description** | ***2026*** |
| Cash consideration | $7000111 |
| Net working capital adjustment | (157394) |
| Equity portion of consideration | 544195 |
| Earnout portion of consideration | 1780000 |
| Selling expense at closing | 2000 |
| Fair value of consideration transferred | $9168912 |

---

The following table summarizes the preliminary allocation of the fair value of consideration transferred to assets acquired and liabilities assumed as of the AML Acquisition Date:

---

| | |
|:---|:---|
|  | ***Preliminary as of*** |
|  | ***March 31,*** |
| **Description** | ***2026*** |
| **Assets:** |  |
| Accounts receivable | $155324 |
| Inventory | 455399 |
| Property and equipment | 182050 |
| Goodwill | 5561256 |
| Other intangible assets | 2980000 |
| **Total assets acquired** | $9334029 |
| **Liabilities:** |  |
| Accounts payable | 27994 |
| Accrued liabilities | 97134 |
| Operating lease liabilities, current | 39989 |
| **Total liabilities assumed** | $165117 |
| **Net assets acquired** | $9168912 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9

------

[**Table of Contents**](#toc)

***Intangible assets*** – All intangible assets acquired in the acquisition of AML are subject to amortization. The fair value of identifiable intangible assets acquired as of the AML Acquisition Date is as follows:

---

| | | |
|:---|:---|:---|
|  |  | ***Useful Lives*** |
| **Intangible Asset** | ***Total*** | ***(Years)*** |
| Backlog | $90000 | 1 |
| Know-how | 930000 | 10 |
| Tradename | 390000 | 10 |
| Customer relationships | 1570000 | 10 |
| **Total** | $2980000 |  |

---

***Goodwill*** – The $5.6 million of goodwill recognized is attributable to AML's assembled workforce and expected synergies related to the expansion of our infrared glass portfolio and manufacturing capabilities. The acquired goodwill is expected to be deductible for Federal income tax purposes. See Note *9, Goodwill and Intangible Assets,* in these Notes to these unaudited Condensed Consolidated Financial Statements for further information.

The Company's unaudited Condensed Consolidated Financial Statements reflect the financial results of AML beginning on the AML Acquisition Date. Revenue generated by AML from the AML Acquisition date through *March 31, 2026* is approximately $1.0 million and is included in our infrared components product group, with net income of approximately $0.3 million.

For the *three* and *nine* months ended *March 31, 2026*, we incurred approximately $0.1 million and $0.2 million in acquisition costs which are included in the unaudited Consolidated Statements of Comprehensive Income in the line item entitled "Selling, general and administrative."

See Note *4, Acquisition of *G5* Infrared,* in these Notes to these unaudited Condensed Consolidated Financial Statements for unaudited consolidated pro forma information.

***4.* Acquisition of *G5* Infrared**

In *February 2025,* the Company acquired *G5* Infrared LLC, a New Hampshire limited liability company (*"G5* Infrared"), pursuant to a Membership Interest Purchase Agreement (the *"G5* MIPA") by and among the Company, *G5* Infrared, the members of *G5* Infrared (collectively, the *"G5* Sellers"), and Kenneth R. Greenslade, solely in his capacity as *G5* Sellers' Representative. The Company has acquired from the *G5* Sellers all of the issued and outstanding membership interests of *G5* Infrared, which closed on *February 18, 2025 (*the *"G5* Acquisition Date").

Net assets and results of operations of *G5* Infrared are reflected in our financial results commencing on the *G5* Acquisition Date. Revenue generated by *G5* Infrared is included in our infrared components and assemblies and modules product groups.

We accounted for the acquisition of *G5* Infrared using the acquisition method of accounting, which required us to measure identifiable assets acquired and liabilities assumed in the acquiree at their fair values as of the *G5* Acquisition Date, with the excess of the consideration transferred over those fair values recorded as goodwill.

The fair value of the aggregate consideration was approximately $27.1 million which consisted of (i) $20.3 million in cash, (ii) 1,972,501 shares of the Common Stock (at a value of $2.47 per share, which was the closing price on the *G5* Acquisition Date), and (iii) potential earnout consideration paid annually in fiscal years *2026* and *2027* subject to achievement of certain revenue and EBITDA targets set forth in the *G5* MIPA. As of the *G5* Acquisition Date, the fair value of consideration transferred consisted of the following:

---

| | |
|:---|:---|
|  | **February 18,** |
| **Description** | **2025** |
| Cash consideration | $20250000 |
| Net working capital adjustment | (423871) |
| Equity portion of consideration | 4872066 |
| Earnout portion of consideration | 3536471 |
| Revenue clawback | (1104471) |
| Fair value of consideration transferred | $27130195 |

---

The fair value of the equity portion of the consideration was determined by multiplying the number of shares issued, 1,972,501, by the fair value of the Common Stock on the *G5* Acquisition Date, which was $2.47. The initial cash consideration at closing was subject to a net working capital adjustment, which was settled in *June 2025.* The *G5* MIPA also included a provision for a clawback amount if *G5* Infrared's actual revenue for the *2024* calendar year was less than $17.3 million. This clawback amount was settled in *June 2025* and is reflected in the determination of the purchase price.

Earnout payments of an aggregate of up to $23.0 million of additional consideration *may* be paid annually in fiscal years *2026* and *2027* subject to achievement of certain minimum EBITDA and revenue targets for the *one* and *two*-year periods beginning on the *first* full calendar month commencing after the *G5* Acquisition Date, as set forth in the *G5* MIPA. If the targets are achieved during the respective periods, LightPath will (i) issue an aggregate number of shares Common Stock equal to 30% of the earnout payment divided by the average close price for the *ten* trading days immediately prior to the *first* anniversary of the earnout commencement date, as defined in the *G5* MIPA, and (ii) pay additional cash consideration in an amount equal to 70% of the earnout payment, in each case to the former *G5* Infrared members. The earnout is considered contingent consideration and is accounted for as a liability initially measured at fair value, with changes during each reporting period recognized in earnings. The portion of the earnout that will be settled in stock will also be accounted for as a liability since the achievement of targets adjusts the number of shares to be issued at settlement based on a variable other than the Company's Common Stock, and therefore it does *not* meet the criteria in ASC *480,* Distinguishing Liabilities from Equity. The fair value of the earnout in the accompanying unaudited Condensed Consolidated Balance Sheet is calculated using a Monte Carlo valuation method, which involves assumptions of revenue and EBITDA forecasts, discount rates and revenue volatility. Significant increases or decreases in any of those assumptions in isolation could result in a significantly higher or lower fair value measurement. The earnout liability is subject to fair value measurement each reporting period. During the quarter ended *March 31, 2026,* the *first* earnout period ended and based on the targets achieved, the *first* earnout payment was made to the *G5* Sellers for $7.3 million in cash and $3.2 million in shares of Common Stock (297,445 shares). As of *March 31, 2026,* the remaining earnout liability was increased to $6.7 million, resulting in a total charge of $12.2 million since *June 30, 2025*, which is included in the "Change in fair value of acquisition liabilities" in the accompanying unaudited Condensed Consolidated Statement of Comprehensive Income (Loss). Subsequently, on *April 16, 2026,* we executed a side letter agreement with the *G5* Sellers which set the year *two* earnout payment amount and accelerated the payment timeline. Pursuant to the agreement, the earnout amount will be $9 million, comprised of $6.3 million in cash and $2.7 million in shares of Common Stock, to be paid after *January 1, 2027* and on or before *January 15, 2027.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

The following table summarizes the preliminary allocation of the fair value of consideration transferred to assets acquired and liabilities assumed as of the *G5* Acquisition Date and the adjustments recognized during the measurement period:

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Measurement** |  |
|  | ***Preliminary as of*** | ***Period*** | ***Final as of*** |
|  | ***March 31,*** | ***Adjustments*** | ***June 30,*** |
| **Description** | ***2025*** | ***Net*** | ***2025*** |
| **Assets:** |  |  |  |
| Accounts receivable | $1897098 | $*—* | $1897098 |
| Inventory | 5065451 | *—* | 5065451 |
| Prepaid expenses and other current assets | 363413 | *—* | 363413 |
| Property and equipment | 1542707 | *—* | 1542707 |
| Operating lease right-of-use asset | 463985 | *—* | 463985 |
| Goodwill | 2977344 | 4012450 | 6989794 |
| Other intangible assets | 19295000 | (5543000) | 13752000 |
| Other assets | 21748 | *—* | 21748 |
| **Total assets acquired** | $31626746 | $(1530550) | $30096196 |
| **Liabilities:** |  |  |  |
| Accounts payable | 1981164 | *—* | 1981164 |
| Accrued liabilities | 336263 | *—* | 336263 |
| Operating lease liabilities, current | 268972 | *—* | 268972 |
| Deferred tax liabilities, noncurrent | 1174650 | (1037668) | 136982 |
| Operating lease liabilities, noncurrent | 242620 | *—* | 242620 |
| **Total liabilities assumed** | $4003669 | $(1037668) | $2966001 |
| **Net assets acquired** | $27623077 | $(492882) | $27130195 |

---

Measurement period adjustments include fair value adjustments during the fiscal quarter ended *June 30, 2025,* primarily related to refined assumptions in the valuation of the earnout consideration, and intangible assets such as backlog, customer relationships and know-how intangible assets. Deferred tax liabilities were adjusted for the revised intangible asset values, and for the refined tax rate apportionment calculation. The net impact of the aforementioned adjustments resulted in an increase to goodwill. There have been *no* further adjustments since *June 30, 2025.*

***Intangible assets*** – All intangible assets acquired in the acquisition of *G5* Infrared are subject to amortization. The fair value of identifiable intangible assets acquired as of the *G5* Acquisition Date is as follows:

---

| | | |
|:---|:---|:---|
|  |  | **Useful Lives** |
| **Intangible Asset**  | **Total** | **(Years)** |
| Backlog | $361000 | 1 |
| Know-how | 4801000 | 10 |
| Tradename | 3450000 | 15 |
| Customer relationships | 5140000 | 15 |
| **Total** | $13752000 |  |

---

The fair value of intangible assets is estimated using the multi-period excess earnings approach for acquired customer relationships and the relief from royalty method for the acquired trade names and know-how. All of these Level *3* fair value methods are income-based valuation approaches, which require judgment to estimate appropriate discount rates, revenue forecasts, useful lives, royalty rates related to the trade names and know-how intangible assets, and profitability assumptions related to customer relationships. The acquired intangible assets are *not* expected to be deductible for New Hampshire state income tax purposes, which resulted in a deferred tax liability of $0.1 million.

***Goodwill*** – The $7.0 million of goodwill recognized is attributable to *G5* Infrared's market presence, the assembled workforce and established operating infrastructure. The acquired goodwill is expected to be deductible for Federal income tax purposes. See Note *9, Goodwill and Intangible Assets,* in these Notes to these unaudited Condensed Consolidated Financial Statements for further information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

***Acquisition Financing***

In conjunction with the financing of the acquisition of *G5* Infrared, the Company designated a new series of preferred stock, "Series G Convertible Preferred Stock", which is convertible into shares of Common Stock. Concurrent with the entry into the *G5* MIPA on *February 13, 2025,* we entered into (i) a Securities Purchase Agreement (the "Securities Purchase Agreement") by and among the Company and North Run Capital, AIGH Investment Partners, LP, WVP Emerging Manager Offshore Fund LLC, the Lytton-Kambara Foundation and Alice W. Lytton Family LLC (collectively, the "Series G Purchasers"), (ii) a Class A Common Securities Purchase Agreement by and between the Company and Lytton-Kambara Foundation (the "Class A Purchaser"), and (iii) *two* senior secured promissory notes in an aggregate principal amount of $5.2 million (the "Acquisition Notes")(see Note *14, Loans Payable*) for total proceeds of approximately $32.2 million, inclusive of the conversion of the bridge promissory note (the "Bridge Note") (see Note *14, Loans Payable*), and before deducting offering expenses of $2.2 million incurred by the Company, which was used to fund, in part, the cash consideration payable in connection with the acquisition of *G5* Infrared. Pursuant to the Securities Purchase Agreement, the Series G Purchasers purchased from the Company (i) an aggregate of approximately 24,956 shares of Series G Convertible Preferred Stock, (ii) warrants to purchase an aggregate of 4,352,774 shares of Common Stock, with an exercise price of $2.58 per share (the "Series G Purchasers Warrants"), and (iii) the Acquisition Notes, which were convertible into shares of Series G Convertible Preferred Stock limited to failure to achieve a certain EBITDA threshold. The Securities Purchase Agreement closed on *February 18, 2025.* As discussed further in Note *14, Loans Payable*, each of the Acquisition Notes and the Bridge Note were paid in full as of *December 31, 2025.*

Each share of Series G Convertible Preferred Stock has an initial stated value of $1,000.00 per share, and bears dividends at a per annum rate of 6.5%. With respect to dividends, distributions and payments upon liquidation, dissolution or winding up of the Company, the Series G Convertible Preferred Stock ranks senior to all classes of the Common Stock, unless the Lead Investor (as defined in the Securities Purchase Agreement) consents to the creation of parity or senior securities. Each holder *may* convert shares of Series G Convertible Preferred Stock into shares of Common Stock at a conversion rate equal to the conversion amount divided by the conversion price. The initial conversion price is $2.15 per share, subject to adjustment for stock splits, stock dividends, recapitalizations, reorganizations, reclassifications, combinations, subdivisions and similar events as provided in the Certificate of Designation. Based on an analysis of the Series G Convertible Preferred Stock, it was concluded that they are more akin to an equity-type instrument. Economic characteristics and risks of an equity-linked conversion option are clearly and closely related to an equity-type host; thus, the conversion option embedded in the Series G Convertible Preferred Stock do *not* require bifurcation or liability classification under ASC *815,* Derivatives and Hedging. It also does *not* meet the definition of being mandatorily redeemable under ASC *480*-*10*-*20* because it does *not* embody an unconditional obligation to redeem the instrument. The Series G Convertible Preferred Stock is redeemable at the option of the holder after the *5* year Guaranteed Term, thus, it should be classified as mezzanine equity, outside of permanent equity. The Series G Convertible Preferred was valued using a Binomial Lattice Model which considers the ability of the investor to convert the instrument into Common Stock at any time, and for the Company's call option and the investor's put option which are available after *5* years. The model incorporates transaction details such as stock price, contractual conversion price, dividend yield, discount rates, expected volatility, market credit spread, estimated yield and investor exercise behavior. The Company elected to recognize any redemption value changes immediately as they occur and adjust the carrying amount to equal the redemption value at each reporting period.

***Unaudited supplemental pro forma information***

The following table presents unaudited pro forma financial results of the operations acquired with *G5* Infrared and AML. The pro forma results include adjustments to remove costs directly attributable to the acquisition, such as transaction-related costs and the loss on extinguishment of debt (as described in Note *14, Loans Payable,* to these Consolidated Financial Statements). The pro forma results were prepared as if the acquisition of *G5* Infrared was completed on the *first* day of our fiscal *2024, July 1, 2023,* and as if the acquisition of AML was completed on the *first* day of our fiscal year *2025, July 1, 2024.* The pro forma results do *not* include any integration synergies and are *not* necessarily indicative of our results of operations that actually would have been obtained had the acquisitions of *G5* Infrared and AML been completed for the periods presented, or which *may* be realized in the future.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** | ***Nine Months Ended March 31,*** | ***Nine Months Ended March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Revenue | $19186814 | $11277802 | $52117840 | $39261202 |
| Loss before income taxes | $(3788897) | $(3103705) | $(15630482) | $(5869058) |

---

***5.* Acquisition of Visimid Technologies**

In *July 2023,* the Company acquired Liebert Consulting LLC, dba Visimid Technologies ("Visimid"), pursuant to a Membership Interest Purchase Agreement dated as of *July 25, 2023 (*the "Visimid Acquisition Date").

The Company's unaudited Condensed Consolidated Financial Statements reflect the financial results of Visimid beginning on the Visimid Acquisition Date. The purchase price included $1.0 million in cash, $1,550,000 of restricted stock, $150,000 of assumed bank debt, and an earnout which is contingent upon the award and completion of a specific customer contract. Of the restricted stock payable as part of the purchase price, $150,000 (81,610 shares) was issued at closing, with the remaining balance issued in *four* equal installments of $350,000 each, on *January 1, 2024, July 1, 2024, January 1, 2025* and *July 1, 2025.* The number of shares was based on the average closing price of the Common Stock, as reported by Bloomberg, for the *five* trading days prior to each stock issuance. For the *January 1, 2024* installment, 267,176 shares were issued; for the *July 1, 2024* installment, 279,553 shares were issued; for the *January 1, 2025* installment, 102,700 shares were issued; and for the *July 1, 2025* installment, 112,323 shares were issued, which was the final equity installment.

The total purchase price, net of cash acquired and including the estimated potential earnout, is approximately $2.7 million, based on present values as of the Visimid Acquisition Date. Of this amount, $600,000 was paid at closing, cash installments of $150,000, $125,000 and $125,000 were paid in *October 2023, January 2024* and *September 2024,* respectively, per the terms of the purchase agreement. The balance of the estimated potential earnout was accrued and is included in Accrued liabilities in the unaudited Condensed Consolidated Balance Sheet as of *March 31, 2026.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

[**Table of Contents**](#toc)

***6.* Revenue**

*Product Revenue*

We are a manufacturer of infrared imaging cameras, optical assemblies, optical components and infrared materials. Optical components include precision molded glass aspheric optics, molded and diamond-turned infrared aspheric lenses, and other optical elements produced using other fabrication techniques. We design, develop, manufacture, and distribute optical systems, assemblies and components utilizing advanced optical manufacturing processes, multidisciplinary engineering and manufacturing technologies, and assembly and integration services. We also provide engineering services and perform research and development for optical solutions for a wide range of optics markets.

*Revenue Recognition*

Revenue is generally recognized upon transfer of control, including the risks and rewards of ownership, of products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We generally bear all costs, risk of loss, or damage and retain title to the goods up to the point of transfer of control of products to customers. Shipping and handling costs are included in the cost of goods sold. We present revenue net of sales taxes and any similar assessments.

Customary payment terms are granted to customers, based on credit evaluations. We currently do *not* have any contracts where revenue is recognized, but the customer payment is contingent on a future event. We record deferred revenue when cash payments are received or due in advance of revenue recognition. Deferred revenue was $1.2 million and $0.5 million as of *March 31, 2026* and *June 30, 2025*, respectively, and is included in accrued liabilities in the unaudited Condensed Consolidated Balance Sheets. The balance of deferred revenue as of *June 30, 2025* was recognized during the fiscal quarter ended *September 30, 2025.*

*Nature of Products*

Revenue from the sale of infrared cameras, optical components and assemblies is recognized upon transfer of control, including the risks and rewards of ownership, to the customer. The performance obligations for the sale of optical components and assemblies are satisfied at a point in time, generally upon shipment. Product development agreements for engineering services are generally short-term in nature, with revenue recognized upon satisfaction of the performance obligation, and transfer of control of the agreed-upon deliverable. Visimid has *one* longer-term order with a defense customer which includes both product development and hardware deliverables where similar revenue recognition criteria are applied.

We categorize our products into *four* product groups: infrared components, visible components, assemblies and modules, and engineering services.

Revenue by product group for the *three* and *nine* months ended *March 31, 2026* and *2025* was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Infrared components | $6147583 | $3640517 | $15423577 | $9363477 |
| Visible components | 3971593 | 2838346 | 11254273 | 8901076 |
| Assemblies and modules | 8434403 | 1852482 | 21504936 | 3803364 |
| Engineering services | 596235 | 836282 | 2376961 | 2924920 |
| Total revenue | $19149814 | $9167627 | $50559747 | $24992837 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

[**Table of Contents**](#toc)

***7.* Inventories**

The components of inventories include the following:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***June 30,*** |
|  | ***2026*** | ***2025*** |
| Raw materials | $7152348 | $4507764 |
| Work in process | 6088970 | 7321779 |
| Finished goods | 2468766 | 3053726 |
| Allowance for obsolescence | (2365379) | (2024431) |
| &nbsp;&nbsp;&nbsp; Total inventories, net | $13344705 | $12858838 |

---

During the *nine* months ended *March 31, 2026* and *2025,* the Company evaluated all allowed items and disposed of approximately $0.2 million and $0.1 million, respectively, of inventory items and wrote them off against the allowance for obsolescence.

The value of tooling in raw materials, net of the related allowance for obsolescence, was approximately $0.8 million and $1.1 million as of *March 31, 2026* and *June 30, 2025*, respectively.

***8.* Property and Equipment**

Property and equipment are summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Estimated Lives*** | ***March 31,*** | ***June 30,*** |
|  | ***(Years)*** | ***2026*** | ***2025*** |
| Manufacturing equipment | 5 - 10 | $25861656 | $24257063 |
| Computer equipment and software | 3 - 5 | 1519200 | 1449494 |
| Furniture and fixtures | 5 | 447963 | 398800 |
| Leasehold improvements | 5 - 10 | 9733615 | 9411482 |
| Construction in progress |  | 1863472 | 1536968 |
| Total property and equipment |  | 39425906 | 37053807 |
| Less accumulated depreciation and amortization |  | (23597667) | (21189746) |
| Total property and equipment, net |  | $15828239 | $15864061 |

---

Depreciation expense was $0.8 million and $0.7 million for the *three*-month periods ended *March 31, 2026* and *2025*, respectively, and $2.3 million and $1.9 million for the *nine*-month periods ended *March 31, 2026* and *2025*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

***9.* Goodwill and Intangible Assets**

The increase in goodwill of $5.6 million during the *nine* months ended *March 31, 2026* was due to the acquisition of AML. The Company is in the process of obtaining *third*-party valuations of certain intangible assets; thus, the provisional measurement of goodwill and intangible assets are subject to change. See Note *3, Acquisition of Amorphous Materials*, to these unaudited Condensed Consolidated Financial Statements, for more information. There have been *no* events or changes in circumstances that indicate the carrying value of goodwill *may not* be recoverable.

Amortizable intangible assets were comprised of:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Useful Lives*** | ***March 31,*** | ***June 30,*** |
|  | ***(Years)*** | ***2026*** | ***2025*** |
| Customer relationships | 10 - 15 | $10422300 | $8852300 |
| Know-how | 8 - 10 | 9928304 | 8998304 |
| Tradenames | 8 - 15 | 8096418 | 7706418 |
| Backlog | 1 | 914525 | 824525 |
| Total intangible assets |  | 29361547 | 26381547 |
| Less accumulated amortization |  | (11771919) | (10393624) |
| Total intangible assets, net |  | $17589628 | $15987923 |

---

Future amortization of intangible assets is as follows:

---

| | |
|:---|:---|
| Fiscal year ending: |  |
| June 30, 2026 (remaining three months) | $455026.0 |
| June 30, 2027 | 1780543.0 |
| June 30, 2028 | 1730103.0 |
| June 30, 2029 | 1730103.0 |
| June 30, 2030 | 1730103.0 |
| After June 30, 2030 | 10163750.0 |
|  | $17589628.0 |

---

***10.* Income Taxes**

A summary of our total income tax expense and effective income tax rate for the *three* and *nine* months ended *March 31, 2026* and *2025* is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Loss before income taxes | $(4014897) | $(3482429) | $(16201482) | $(7657010) |
| Income tax provision | $91390 | $100031 | $203216 | $160192 |
| Effective income tax rate | -2% | -3% | -1% | -2% |

---

The difference between our effective tax rates in the periods presented above and the federal statutory rate is due to the mix of taxable income and losses generated in our various tax jurisdictions, which include the United States (the "U.S."), the People's Republic of China, and the Republic of Latvia. For the *three* and *nine* months ended *March 31, 2026* and *2025*, income tax expense was primarily related to income taxes from our operations in China and Chinese withholding taxes on payments from our wholly-owned subsidiary, LightPath Optical Instrumentation (Zhenjiang) Co., Ltd. ("LPOIZ"), to LightPath for administrative services rendered.

We record net deferred tax assets to the extent we believe it is more likely than *not* that some portion or all of these assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As of *March 31, 2026* and *June 30, 2025,* our net deferred tax assets are related to the U.S. jurisdiction and we have provided a valuation allowance to reduce the deferred tax assets to the net amount we estimate is more-likely-than-*not* to be realized. Our net deferred tax assets as of *March 31, 2026* and *June 30, 2025* consist primarily of federal and state tax credits with indefinite carryover periods. The net deferred tax liabilities as of *March 31, 2026* and *June 30, 2025* are related to LPOIZ, primarily resulting from timing differences related to accelerated depreciation on fixed assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

*U.S. Federal and State Income Taxes*

Our U.S. federal and state statutory income tax rate is estimated to be 25.5%. Based on our current assessment of the valuation allowance position on our net deferred tax assets, no additional tax expense or benefit is expected to be recorded on pre-tax income or losses generated in the U.S.

On *July 4, 2025,* the One Big Beautiful Bill Act was enacted ("OBBBA"), introducing significant and wide-ranging changes to the U.S. federal tax system. Significant components include restoration of *100%* accelerated tax depreciation on qualifying property including expansion to cover qualified production property. Another major aspect includes the return to immediate expensing of domestic research and experimental expenditures ("R&E") which in some cases *may* include retroactive application back to *2021* for businesses with gross receipts of less than *$31.0* million or accelerated tax deductions of R&E that was previously capitalized for larger businesses. The legislation also reinstates EBITDA-based interest deductions for tax purposes and makes several business tax incentives permanent. Less favorable business provisions include limitations on tax deductions for charitable contributions.

The Company continues to assess the potential impact of this legislation on its future financial position, results of operations, and cash flows. In accordance with GAAP, the effects will be recognized in the period of enactment. While we do *not* currently anticipate that the provisions of OBBBA will have a material impact, we are currently evaluating any such impacts on a go-forward basis.

*Income Tax Law of the People*'*s Republic of China*

Our Chinese subsidiary, LPOIZ, is governed by the Income Tax Law of the People's Republic of China. As of *March 31, 2026*, LPOIZ was subject to a statutory income tax rate of 15%. The net deferred tax liabilities included in these unaudited Condensed Consolidated Balance Sheets as of *March 31, 2026* and *June 30, 2025* are related to LPOIZ, primarily related to timing differences related to accelerated depreciation on fixed assets.

The Company routinely declares intercompany dividends to remit a portion of the earnings of its foreign subsidiaries to the U.S. parent company. The Company also intends to reinvest a portion of the earnings generated by its foreign subsidiaries. The Company accrues withholding taxes on the portion of LPOIZ's earnings that it intends to repatriate. Accrued and unpaid withholding taxes were approximately $32,000 as of both *March 31, 2026* and *June 30, 2025*. Other than these withholding taxes, these intercompany dividends have *no* impact on the unaudited Condensed Consolidated Financial Statements.

*Law of Corporate Income Tax of Latvia*

Our Latvian subsidiary, ISP Optics Latvia, SIA ("ISP Latvia"), is governed by the Law of Corporate Income Tax of Latvia. Effective *January 1, 2018,* the Republic of Latvia enacted tax reform with the following key provisions: (i) corporations are *not* subject to income tax, but are instead subject to a distribution tax on distributed profits (or deemed distributions, as defined) and (ii) the rate of tax was changed to 20%; however, distribution amounts are *first* divided by *0.8* to arrive at the profit before tax amount, resulting in an effective tax rate of 25%. As a transitional measure, distributions of earnings prior to *January 1, 2018* were *not* subject to tax if declared prior to *December 31, 2019.* ISP Latvia declared an intercompany dividend to be paid to ISP Optics Corporation ("ISP"), its U.S. parent company, for the full amount of earnings accumulated prior to *January 1, 2018.* Distributions of this dividend have been fully settled and we currently do *not* intend to distribute any earnings generated after *January 1, 2018.* If, in the future, we change such intention, we will accrue distribution taxes, if any, as profits are generated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

***11.* Stock-Based Compensation**

Our directors, officers, and key employees are granted stock-based compensation through our *2002* Amended and Restated Omnibus Incentive Plan, as amended (the *"2002* Omnibus Plan"), through *October 2018* and after that date, through our *2018* Stock and Incentive Compensation Plan (the *"2018* SICP"). Such stock-based compensation *may* include, among other things, incentive stock options, non-qualified stock options, restricted stock awards ("RSAs") and restricted stock units ("RSUs"). The *2018* SICP is administered by the Compensation Committee of the Board of Directors. To date, our stockholders approved an aggregate of 13,715,625 shares of our Common Stock for issuance pursuant to awards granted under the *2002* Omnibus Plan or SICP. As of *March 31, 2026*, 2,632,750 shares of Common Stock were authorized and available for issuance pursuant to awards granted under the *2018* SICP. The Company's executive officers are eligible to earn incentive compensation consisting of equity-based awards, as well as cash bonuses, based on the achievement of certain individual and/or Company performance goals set by the Compensation Committee.

Stock-based compensation expense is based primarily on the fair value of the award as of the grant date and is recognized as an expense over the requisite service period.

The following table shows total stock-based compensation expense for the *three* and *nine* months ended *March 31, 2026* and *2025*, the majority of which is included in selling, general and administrative ("SG&A") expenses in these unaudited Condensed Consolidated Statements of Comprehensive Income (Loss):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Stock options | $207136 | $10574 | $306895 | $32192 |
| RSAs | 157056 | 138781 | 302900 | 304999 |
| RSUs | 198774 | 89779 | 651782 | 407964 |
| Total | $562966 | $239134 | $1261577 | $745155 |

---

We also adopted the LightPath Technologies, Inc. Employee Stock Purchase Plan (the *"2014* ESPP"). The *2014* ESPP permits employees to purchase Common Stock through payroll deductions, subject to certain limitations. The *2014* ESPP expired in *January 2025* and a new Employee Stock Purchase Plan (*"2025* ESPP") was approved by the stockholders on *June 16, 2025* with the *first* offering period beginning *July 1, 2025.* The *first* purchase of shares under the *2025* ESPP occurred in *January 2026,* immediately following the offering period ended *December 31, 2025.* The discount for the *nine* months ended *March 31, 2026* and *2025* was $2,500 and $1,500, respectively, included in SG&A expenses in these unaudited Condensed Consolidated Statements of Comprehensive Income (Loss), which represents the value of the 10% discount given to the employees purchasing stock under the *2025* ESPP and *2014* ESPP, respectively.

*Grant Date Fair Values and Underlying Assumptions; Contractual Terms*

We estimate the fair value of each stock option as of the date of grant, using the Black-Scholes-Merton pricing model. The fair value of *2014* ESPP and *2025* ESPP shares is the amount of the discount the employee obtains at the date of the purchase transaction.

Most stock options granted vest ratably over two to four years and are generally exercisable for ten years. The assumed forfeiture rates used in calculating the fair value of RSA and RSU grants was 0%, and the assumed forfeiture rates used in calculating the fair value of options for performance and service conditions were 20% for each of the *nine* months ended *March 31, 2026* and *2025*. The volatility rate and expected term are based on *seven*-year historical trends in Common Stock closing prices and actual forfeitures. The interest rate used is the U.S. Treasury interest rate for constant maturities.

The Company estimated the fair value of each stock award as of the date of grant using the following assumptions:

---

| | |
|:---|:---|
|  | ***Nine Months Ended*** |
|  | ***March 31,*** |
|  | ***2026*** |
| Weighted-average expected volatility | 74.0% |
| Dividend yields | 0% |
| Weighted-average risk-free interest rate | 4.2% |
| Weighted-average expected term, in years | 7.5 |

---

No stock options were granted during the *nine* months ended *March 31, 2025*.

In *March 2026,* we granted stock options to certain executives with vesting criteria linked to the Company's financial performance. The stock compensation expense related to these grants reflects the application of estimated probability assumptions related to the achievement of those financial targets. These assumptions will be evaluated for adjustment each fiscal quarter.

*Restricted Stock Awards*

RSAs are granted primarily to our executive officers, employees and consultants, and typically vest over a one to three year period from the date of grant, although some *may* vest immediately upon grant. The stock underlying RSAs is issued upon vesting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

*Restricted Stock Units*

RSUs are granted primarily to our directors, although RSU awards *may* also be made to executive officers, employees and consultants. RSUs typically vest over a one to four year period from the date of grant, although some *may* vest immediately upon grant.

*Information Regarding Current Share-Based Compensation Awards*

A summary of the activity for share-based compensation awards in the *nine* months ended *March 31, 2026* is presented below:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Stock Options*** | ***Stock Options*** | ***Stock Options*** | ***Restricted Stock Units (RSUs)*** | ***Restricted Stock Units (RSUs)*** | ***Restricted Stock Awards (RSAs)*** | ***Restricted Stock Awards (RSAs)*** |
|  |  | ***Weighted-*** | ***Weighted-*** |  | ***Weighted-*** |  | ***Weighted-*** |
|  |  | ***Average*** | ***Average*** |  | ***Average*** |  | ***Average*** |
|  |  | ***Exercise*** | ***Remaining*** |  | ***Remaining*** |  | ***Remaining*** |
|  | ***Shares*** | ***Price*** | ***Contract*** | ***Shares*** | ***Contract*** | ***Shares*** | ***Contract*** |
| **June 30, 2025** | 720619 | $2.10 | 7.2 | 1080953 | 0.6 | 121912 | 1.2 |
| Granted | 3441565 | $10.53 |  | 564031 |  | 56158 | *—* |
| Exercised | (7385) |  |  | (184279) |  | (123522) | *—* |
| Cancelled/Forfeited | (9579) | $1.74 |  |  |  |  | *—* |
| **March 31, 2026** | 4145220 | $9.06 | 9.4 | 1460705 | 1.1 | 54548 | 1.4 |
| Awards exercisable/vested as of |  |  |  |  |  |  |  |
| **March 31, 2026** | 355696 | $1.99 | 4.2 | 776804 | *—* |  | *—* |
| Awards unexercisable/vested as of |  |  |  |  |  |  |  |
| **March 31, 2026** | 3789524 | $9.72 | 9.9 | 683901 | 2.4 | 54548 | 1.4 |
|  | 4145220 |  |  | 1460705 |  | 54548 |  |

---

As of *March 31, 2026*, there was approximately $24.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements (including stock options, RSAs and RSUs) granted. The expected compensation cost to be recognized is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fiscal Year Ending:** | ***Stock Options*** | ***RSAs*** | ***RSUs*** | ***Total*** |
| June 30, 2026 (remaining three months) | $1351347 | $139224 | $881960 | $2372531 |
| June 30, 2027 | 5419964 | 362619 | 2619614 | 8402197 |
| June 30, 2028 | 5399788 | 62582 | 1893706 | 7356076 |
| &nbsp;&nbsp;&nbsp; June 30, 2029 | 3706822 |  | 1275206 | 4982028 |
| June 30, 2030 | 515354 |  |  | 515354 |
| June 30, 2031 | 371337 |  |  | 371337 |
|  | $16764612 | $564425 | $6670486 | $23999523 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

***12.* Earnings (Loss) Per Share** 

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of Common Stock outstanding during each period presented. The computation of diluted earnings (loss) per share further assumes the potential dilutive effect of potential Common Stock using the treasury-stock method and if-converted method, as applicable. During periods in which the average market price of the Company's common stock is above the applicable conversion price of the Company's convertible notes, the impact of conversion would be dilutive and such dilutive effect is reflected in diluted EPS. As a result, in periods where the average market price of the Company's common stock is above the conversion price, under the if-converted method, the Company calculates the number of shares issuable under the terms of the convertible notes based on the average market price of the stock during the period, and includes that number in the total diluted shares outstanding for the period. The Series G Purchasers Warrants and the Series G Convertible Preferred Stock are participating securities as the holders of such instruments participate in the event a dividend is paid on the Common Stock, however the holders do *not* have a contractual obligation to share in the Company's losses. As such, losses are attributed entirely to common stockholders. The computations for basic and diluted earnings (loss) per share of Common Stock are described in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Net loss | $(4106287) | $(3582460) | $(16404698) | $(7817202) |
| Accretion of dividends on Series G preferred |  | (14751134) |  | (14751134) |
| Net loss attributable to stockholders | $(4106287) | $(18333594) | $(16404698) | $(22568336) |
| Weighted-average common shares outstanding: |  |  |  |  |
| Basic number of shares | 58628741 | 41363643 | 49572872 | 40209657 |
| Diluted number of shares | 58628741 | 41363643 | 49572872 | 40209657 |
| Loss per common share: |  |  |  |  |
| Basic | $(0.07) | $(0.44) | $(0.33) | $(0.56) |
| Diluted | $(0.07) | $(0.44) | $(0.33) | $(0.56) |

---

The following potential dilutive shares were *not* included in the computation of diluted earnings (loss) per share of Common Stock, as their effects would be anti-dilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Options to purchase common stock | 974741 | 394527 | 816317 | 486965 |
| RSUs and RSAs | 1124652 | 1131004 | 1170969 | 1285881 |
| Series G convertible preferred & warrants | 3510464 | 2890176 | 4793299 | 935057 |
|  | 5609857 | 4415707 | 6780585 | 2707903 |

---

We have also accrued for certain acquisition liabilities related to the *G5* Infrared and AML acquisitions, a portion of which is expected to be settled in shares of Common Stock, however the number of shares to be issued is dependent upon the stock price at or near the date of settlement. As the number of shares is *not* known, they have *not* been included in the above potential dilutive shares. See Note *3, Acquisition of Amorphous Materials* and Note *4, Acquisition of *G5* Infrared,* to these unaudited Condensed Consolidated Financial Statements, for more information.

All of the Series G Purchasers Warrants were exercised during the *nine* months ended *March 31, 2026,* by means of "cashless exercise" as defined in the respective warrant agreements. As of *March 31, 2026, no* Series G Purchasers Warrants were outstanding.

During the *three* months ended *March 31, 2026,* certain holders of Series G Convertible Preferred Stock elected "optional conversion," as defined in the certificate of designations. A total of 7,610 shares of Series G Convertible Preferred Stock, which have a stated value of $1,000 per share, were converted into 3,539,379 shares of Common Stock at a conversion price of $2.15 per share. As a result of the conversion, we reclassified $10.4 million from temporary equity to common stock and additional paid-in capital. Following the conversions, 17,346 shares of Series G Convertible Preferred Stock remained issued and outstanding as of *March 31, 2026.*

***13.* Leases**

Our leases primarily consist of operating leases related to our facilities located in Orlando, Florida; Plano, Texas; Hudson, New Hampshire; Riga, Latvia; and Zhenjiang, China, and finance leases related to certain equipment located in Orlando, Florida and Riga, Latvia. The operating leases for facilities are non-cancelable operating leases, with terms ending at various times through *2034.* We typically include options to renew (or terminate) in our lease term, and as part of our right-of-use ("ROU") assets and lease liabilities, when it is reasonably certain that we will exercise such options. We currently have *eighteen* finance lease agreements entered into during fiscal years *2024* thru *2026* with terms ranging from three to five years. The finance leases are for computer and manufacturing equipment.

Our operating lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. One of our operating leases includes renewal options, which were *not* included in the measurement of the operating lease ROU assets and related lease liabilities. The lease on the premises comprising our primary facility in Orlando, Florida. The Orlando Facility lease was amended in *April 2021,* and again in *September 2021,* to expand the space. The lease term was extended and will expire on *March 31, 2034.*

Our wholly-owned subsidiary, *G5* Infrared, has a lease agreement for a manufacturing and office facility in Hudson, New Hampshire, which expires *December 31, 2031.* The Company's wholly-owned subsidiary, Visimid, has a lease agreement for a manufacturing and office facility in Plano, Texas, which commenced *September 1, 2025* for a five-year term. The prior facility was relocated to this larger facility, and the lease of the prior facility, which was set to expire *October 31, 2026,* was terminated in *March 2026* pursuant to a mutual agreement with the lessor.

Our wholly-owned subsidiary, LPOIZ, has a lease agreement for a manufacturing and office facility in Zhenjiang, China, which expires *December 31, 2027.* ISP's wholly-owned subsidiary, ISP Latvia, has two lease agreements for a manufacturing and office facility in Riga, Latvia, which leases expire *December 31, 2030.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

[**Table of Contents**](#toc)

The components of lease expense for the *three* and *nine* months ended *March 31, 2026* and *2025* were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Operating lease cost | $319082 | $265245 | $883194 | $803725 |
| Finance lease cost: |  |  |  |  |
| Depreciation of lease assets | 52274 | 45466 | 142530 | 126198 |
| Interest on lease liabilities | 19717 | 18105 | 54547 | 49194 |
| Total finance lease cost | 71991 | 63571 | 197077 | 175392 |
| Total lease cost | $391073 | $328816 | $1080271 | $979117 |

---

Supplemental balance sheet information related to the leases as of *March 31, 2026* and *June 30, 2025* was as follows:

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***March 31,*** | ***June 30,*** |
|  | ***Classification*** | ***2026*** | ***2025*** |
| **Assets:** |  |  |  |
| Operating lease assets | *Operating lease assets* | $8406283 | $7429378 |
| Finance lease assets | Property and equipment, net<sup>(1)</sup> | 1044445 | 920569 |
| Total lease assets |  | $9450728 | $8349947 |
| **Liabilities:** |  |  |  |
| Current: |  |  |  |
| Operating leases | *Operating lease liabilities, current* | $1177423 | $1254062 |
| Finance leases | *Finance lease liabilities, current* | 271015 | 206518 |
| Noncurrent: |  |  |  |
| Operating leases | *Operating lease liabilities, less current portion* | 9197980 | 8326250 |
| Finance leases | *Finance lease liabilities, less current portion* | 460316 | 421363 |
| Total lease liabilities |  | $11106734 | $10208193 |

---

<sup>(*1*)</sup> Finance lease assets were recorded net of accumulated depreciation of approximately $0.4 million and $0.3 million as of *March 31, 2026* and *June 30, 2025*, respectively.

Lease term and discount rate information related to leases was as follows:

---

| | |
|:---|:---|
|  | ***March 31,*** |
| **Lease Term and Discount Rate** | ***2026*** |
| Weighted Average Remaining Lease Term (in years) |  |
| Operating leases | 7.2 |
| Finance leases | 2.8 |
| Weighted Average Discount Rate |  |
| Operating leases | 3.1% |
| Finance leases | 9.2% |

---

Supplemental cash flow information was as follows for the *nine* months ended *March 31, 2026* and *2025*:

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| **Cash paid for amounts included in the measurement of lease liabilities:** |  |  |
| Operating cash used for operating leases | $1056876 | $887180 |
| Operating cash used for finance leases | $54548 | $49194 |
| Financing cash used for finance leases | $168089 | $133711 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

[**Table of Contents**](#toc)

Future maturities of lease liabilities were as follows as of *March 31, 2026*:

---

| | | |
|:---|:---|:---|
|  | ***Finance*** | ***Operating*** |
| **Fiscal year ending:** | ***Leases*** | ***Leases*** |
| June 30, 2026 (remaining three months) | $83868 | $397980 |
| June 30, 2027 | 318382 | 1592513 |
| June 30, 2028 | 274265 | 1661520 |
| June 30, 2029 | 116952 | 1660647 |
| June 30, 2030 | 23779 | 1705603 |
| Thereafter | 18278 | 4926194 |
| Total future minimum payments | 835524 | 11944457 |
| Less imputed interest | (104193) | (1569054) |
| Present value of lease liabilities | $731331 | $10375403 |

---

***14.* Loans Payable** 

As of *March 31, 2026*, loans payable consisted of *one* equipment loan. The Acquisition Notes, as defined in Note *4, Acquisition of *G5* Infrared*, were paid in full during the quarter ended *December 31, 2025.*

***Acquisition Notes***

On *February 18, 2025,* in connection with the acquisition of *G5* Infrared, we executed and delivered the Acquisition Notes, effective as of the *G5* Acquisition Date. The Acquisition Notes accrued interest at the rate between 10-12% per annum (12% as of the date of extinguishment, *December 31, 2025),* based on the ratio of indebtedness to EBITDA of the Company. We determined the embedded features related to the payment of variable interest and upon an event of default are clearly and closely related to the Acquisition Notes, and are therefore *not* bifurcated from the Acquisition Notes. The Acquisition Notes would have matured on *February 18, 2027,* the *second* anniversary of the issuance date, but were redeemed by the Company on *December 31, 2025,* prior to the maturity date, at a redemption price equal to the portion of principal so redeemed plus all accrued and unpaid interest thereon. Pursuant to the terms of the Acquisition Notes, since the funds used for redemption were *not* generated internally by Company operations, the redemption amount was multiplied by 102%. We recorded a loss on extinguishment of debt of $0.5 million during the *three* months ended *December 31, 2025,* based on the difference between the carrying value of the debt being extinguished and the redemption amount.

The Acquisition Notes were automatically convertible into shares of Series G Convertible Preferred Stock, which were in turn convertible into shares of Common Stock, if the EBITDA reported by the Company for the calendar year ending *December 31, 2025,* was less than approximately $4.9 million (the "Automatic Note Conversion"). We determined that the Automatic Note Conversion did *not* require bifurcation from the Acquisition Notes as the Automatic Note Conversion is (i) indexed to the Company's own stock, (ii) settled in shares instead of cash, and (iii) only exercisable into a fixed number of shares at a fixed exercise price of $1,000 per share once it is triggered to convert and the conversion price can only be adjusted for standard antidilution provisions. The Acquisition Notes contained other redemption features which the Company determined did *not* require bifurcation from the Acquisition Notes as these are clearly and closely related to the Acquisition Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *21*

------

[**Table of Contents**](#toc)

***Bridge Promissory Note***

On *August 6, 2024,* we entered into the Bridge Note with Lytton-Kambara Foundation (the "Lender" and also the "Class A Purchaser") pursuant to which the Lender extended a loan to the Company in the principal amount of $3.0 million (the "Loan"). The Loan was subject to an original issue discount of 7%. After deducting the original issue discount, fees paid to our placement agent, and certain expenses, the Company received net proceeds of $2.7 million. The Bridge Note was unsecured, bore interest at the rate of 12.5% per annum and had a 1-year term, maturing on *August 6, 2025,* at which time the entire principal amount of the Bridge Note and all accrued but unpaid interest would have been due and payable in full.

The Bridge Note and related accrued interest were settled on *February 18, 2025,* in conjunction with financing for the acquisition of *G5* Infrared.

***Equipment Loans***

In *December 2020,* ISP Latvia received an equipment loan from a *third* party (the *"2020* Equipment Loan"), which party is also a significant customer. The *2020* Equipment Loan was collateralized by certain equipment. The initial advance under the *2020* Equipment Loan was 225,000 EUR (or approximately USD $0.3 million), payable in equal installments over 60 months, the proceeds of which were used to make a prepayment to a vendor for equipment to be delivered at a future date. An additional 225,000 EUR (or approximately USD $0.3 million) was drawn in *September 2021,* which proceeds were paid to the vendor for the equipment, payable in equal installments over 52 months. The *2020* Equipment Loan was paid in full as of *December 31, 2025.*

In *May 2023,* ISP Latvia entered into an equipment loan with a *third* party financial institution (the *"2023* Equipment Loan"). The *2023* Equipment Loan is collateralized by certain equipment. The initial advances under the *2023* Equipment Loan was 260,258 EUR (or approximately USD $0.3 million), the proceeds of which were used to make a prepayment to a vendor for equipment to be delivered at a future date. The final advance for the final payment to the equipment vendor was 132,674 EUR (or approximately USD $0.1 million). The *2023* Equipment Loan is payable over 48 months, with monthly installments that began on *January 1, 2024.* The *2023* Equipment Loan bears interest at the *six*-month EURIBOR rate, plus 2.84% (4.94% as of *March 31, 2026*).

Future maturities of loans payable are as follows:

---

| | |
|:---|:---|
|  | ***Equipment*** |
|  | ***Loan*** |
| **Fiscal year ending:** |  |
| June 30, 2026 (remaining three months) | $28271 |
| June 30, 2027 | 113085 |
| June 30, 2028 | 75390 |
| Total payments | $216746 |
| Less current portion | (113085) |
| Non-current portion | $103661 |

---

***15.* Foreign Operations**

Assets and liabilities denominated in non-U.S. currencies are translated at rates of exchange prevailing on the balance sheet date, and revenues and expenses are translated at average rates of exchange for the period. Gains or losses on the translation of the financial statements of a non-U.S. operation, where the functional currency is other than the U.S. dollar, are reflected as a separate component of equity, which was a cumulative gain of approximately $1.3 million and $1.0 million as of *March 31, 2026* and *June 30, 2025*, respectively. For the *three* months ended *March 31, 2026* and *2025*, we recognized net foreign currency transaction losses of $0.1 million and gains of $0.01 million, respectively. We also recognized net foreign currency transaction losses of $0.1 million and a gain of $0.01 million for the *nine* months ended *March 31, 2026* and *2025*, respectively, included in the Condensed Consolidated Statements of Comprehensive Income (Loss) in the line item entitled "Other income (expense), net."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

[**Table of Contents**](#toc)

Our cash and cash equivalents totaled approximately $55.2 million at *March 31, 2026*. Of this amount, approximately 6% was held by our foreign subsidiaries in China and Latvia. These foreign funds were generated in China and Latvia as a result of foreign earnings. With respect to the funds generated by our foreign subsidiaries in China, the retained earnings of the respective subsidiary must equal at least 50% of its registered capital before any funds can be repatriated through dividends. As of *March 31, 2026*, LPOIZ had approximately $0.5 million in retained earnings available for repatriation, based on earnings accumulated through *December 31, 2025,* the end of the most recent statutory tax year, that remained undistributed as of *March 31, 2026*.

Revenues from foreign countries for the *three* and *nine* months ended *March 31, 2026* and *2025* are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| **Revenues:** |  |  |  |  |
| United States | $10121552 | $5745895 | $24403590 | $16374544 |
| Europe | 6978833 | 2267780 | 20775704 | 4857768 |
| China | 1036800 | 711823 | 3210798 | 2036124 |
| Other Asian countries | 791485 | 260432 | 1478072 | 742950 |
| Rest of world | 221144 | 181697 | 691583 | 981451 |
|  | $19149814 | $9167627 | $50559747 | $24992837 |

---

Long-lived assets located in foreign countries as of *March 31, 2026* and *June 30, 2025* are as follows:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***June 30,*** |
|  | ***2026*** | ***2025*** |
| **Long-lived assets:** |  |  |
| United States | $54256805 | $45982722 |
| Latvia | 4891752 | 4848441 |
| China | 2112990 | 2300608 |
|  | $61261547 | $53131771 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *23*

------

[**Table of Contents**](#toc)

***16.* Segment Reporting**

The Company has one reportable operating segment, the optics segment that is managed on a consolidated basis. The optics segment designs and manufactures products at locations in the U.S., Europe and Asia and manages the business activities on a consolidated basis. Our Chief Operating Decision Maker ("CODM") is the chief executive officer. The CODM assesses performance for the optics segment and decides how to allocate resources based on consolidated net loss that also is reported on the consolidated statements of comprehensive income (loss) as consolidated net loss. The types of products and services from which the optics segment derives its revenues is described in Note *6, Revenue*. The accounting policies of the optics segment are the same as those described in Note *2, Significant Accounting Policies*, to these unaudited Condensed Consolidated Financial Statements. The measure of segment assets is reported on the consolidated balance sheet as total assets. See Note *6, Revenue,* for detail about revenue by product and service group, and Note *15, Foreign Operations*, for geographic information.

The CODM uses consolidated net loss to evaluate income generated from segment assets, and to determine whether to invest in new capabilities related to this segment. The CODM monitors budget to actual results for revenue, gross profit, operating expenses and net loss on a consolidated basis. The CODM reporting package includes non-operating items to reconcile to net income. The following table represents the financial information regularly reviewed by the CODM, in addition to the Consolidated Financial Statements. Interest expense is reported on consolidated statements of comprehensive income (loss) as interest expense, net; depreciation and amortization expense, stock-based compensation expense, and total expenditures for long-lived assets are reported on the consolidated statement of cash flows.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Optics Segment*** | ***Optics Segment*** | ***Optics Segment*** | ***Optics Segment*** |
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***March 31,*** | ***March 31,*** | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** | ***2026*** | ***2025*** |
| Revenue | $19149814 | $9167627 | $50559747 | $24992837 |
| Cost of goods sold | 12193531 | 6503526 | 33100562 | 17553476 |
| Segment gross profit | 6956283 | 2664101 | 17459185 | 7439361 |
| Less: |  |  |  |  |
| Sales & marketing | 865308 | 919174 | 2429171 | 2253941 |
| General & administrative | 3085465 | 1676591 | 7752628 | 4385267 |
| Corporate | 2345513 | 1852594 | 6357818 | 4435797 |
| New product development | 1041794 | 757938 | 2658051 | 1998775 |
| Loss on disposal of equipment |  | 2068 | 4016 | 80505 |
| Amortization of intangible assets | 477245 | 779025 | 1378295 | 1469512 |
| Change in fair value of acquisition liabilities | 3393000 | 130445 | 12234529 | 130445 |
| Interest expense, net | (271641) | 486833 | 282235 | 805246 |
| Other non-operating income (expense), net(1) | 34496 | (458138) | 563924 | (463117*)* |
| Provision for income taxes | 91390 | 100031 | 203216 | 160192 |
| Segment net loss | (4106287) | (3582460) | (16404698) | (7817202*)* |
| **Reconciliation of profit or loss** |  |  |  |  |
| Adjustments and reconciling items |  |  |  |  |
| Consolidated net loss | $(4106287) | $(3582460) | $(16404698) | $(7817202*)* |

---

(*1*) Other non-operating income (expense) includes loss on extinguishment of debt, change in fair value of warrant liability, and other income (expense), net, each of which is presented on the unaudited condensed consolidated statements of comprehensive income (loss).

***17.* Contingencies**

***Legal***

The Company, from time to time, is involved in various legal actions arising in the normal course of business. Management, after reviewing with legal counsel all of these actions and proceedings, believes that the aggregate losses, if any, will *not* have a material adverse effect on the Company's financial position or results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *24*

------

[**Table of Contents**](#toc)

***Potential Impact of Economic Conditions in and Trade Relations with China***

Due to our operations in China, our business, results of operations, financial condition and prospects *may* be influenced to a significant degree by economic, political, legal and social conditions in China. China's economy differs from the economies of other countries in many respects, including with respect to the level of development, growth rate, amount of government involvement, control of foreign exchange and allocation of resources. While China's economy has experienced significant growth over the past several decades, its growth rate has declined in recent years and *may* continue to decline. Deteriorating economic conditions in China generally have led to lower demand for our products in China and thus lower revenues and net income for our subsidiaries in China and the Company overall. A continuation of China's current economic conditions or a further slowdown in the economic growth, an economic downturn, a recession, or other adverse economic conditions in China is likely to have a material adverse effect on our business and results of operations in future quarters.

In addition, China's export limitations on Germanium and Gallium, *two* materials that are commonly used in infrared optical components, are becoming increasingly disruptive to our business with adverse impacts. The initial restrictions imposed in *July 2023* required all international customers to provide an end user statement for approval before receiving an export license. Following that announcement, supply of Germanium was disrupted, though *not* completely stopped. This also resulted in significant price increases in the cost of Germanium material. Following these restrictions we had proactively canceled a number of customer orders for Germanium, to reduce our exposure in case of a supply disruption.

Then, in *December 2024,* China escalated trade tensions with the U.S. by imposing more stringent export restrictions on critical minerals, including Germanium. The Chinese Ministry of Commerce cited national security concerns as the rationale for these measures, which effectively banned shipments of these minerals to the U.S., and significantly limited shipments of those minerals for dual-use applications in many other countries.

As a purchaser of Germanium, we cannot provide any assurance that we will be able to obtain adequate supplies of Germanium, or that the timing or costs of obtaining such raw materials will be acceptable to us. We have taken proactive steps to minimize the orders we accept for Germanium products and therefore minimize our exposure to this risk, and are actively working with our customers to redesign their systems to use our BlackDiamond materials instead of Germanium-based materials. Additionally, we are actively collaborating with our customers to ensure those redesigned systems are tested and qualified as replacements for legacy Germanium-based systems. In some cases, such as complex defense and airborne systems, the re-qualification of such redesigned systems is a lengthy process that can take up to *two* years. In other systems such as commercial systems and also some specific defense systems, this is a faster process, that takes several months.

In *February 2025,* the U.S. announced additional tariffs on goods imported from China, effective immediately, and China announced its intent to follow suit and implement additional tariffs on goods imported to China from the U.S. We utilize a number of strategies to mitigate the current and, hopefully, future impact of tariffs. However, given the uncertainty regarding the current tariffs, as well as the potential for additional trade actions by the U.S. or other countries in the future, any future impact on our operations and financial results is uncertain and these impacts could be more significant than those we have experienced in the past. Further, we can provide *no* assurance that the strategies we implemented to mitigate the impact of such tariffs or other trade actions will continue to be successful. To the extent that our supply chain, costs, sales, or profitability are negatively affected by the tariffs or other trade actions, our business, financial condition, and results of operations *may* be materially adversely affected.

On *February 20, 2026,* the U.S. Supreme Court issued a ruling striking down certain tariffs previously imposed under the International Emergency Economic Powers Act ("IEEPA"). Following the Supreme Court's decision, the U.S. announced its intention to invoke other laws to collect tariffs and announced new tariffs on imports, in addition to any existing non-IEEPA tariffs. There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions *may* be imposed, modified, or suspended, and the impacts of such actions on our business. Furthermore, the Company *may* be eligible to receive refunds of certain tariffs it paid that were levied under the IEEPA. If it is determined that the Company is eligible for refunds, the availability, amount and timing of such refunds is uncertain and subject to further developments. In the event the Company receives a refund of tariffs previously paid, it *may* elect or be required to return a portion of such amounts to customers that provided the Company tariff relief and/or price concessions. Any such obligations could reduce any benefit from a refund. *No* refund asset or liability has been recorded as of *March 31, 2026.*

***Impact of Ongoing Wars***

In *February 2022,* Russian military forces invaded Ukraine. This war has led to ongoing sanctions on Russia, which have had continuing impacts on our supply chain of raw materials, particularly Germanium. Separately, Israel declared war on Hamas in *October 2023.* Initially, this resulted in a temporary increase in our sales, as Israel worked to replace electro-optical systems that in some cases use our materials. Our sales to customers in this region have since stabilized, however, it is still possible that this war could have a negative impact on our business as a result of the overall economic impact in Israel. In addition to the significant defense related market in Israel, we also serve many commercial related applications and work with commercial companies in Israel, and the business of those customers *may* be negatively impacted by the war over time. Given the dynamic nature of this situation, we cannot reasonably estimate the impact of either the Russian-Ukraine conflict or the Israel-Hamas war on our financial condition, results of operations or cash flows into the foreseeable future.

In *February 2026,* the U.S. and Israel launched coordinated military strikes against Iran, which retaliated with missile attacks across the region. Although we do *not* have material operations in the Middle East, the ongoing conflict and any further escalation, including additional military actions, retaliatory measures, sanctions, disruptions to trade or transportation routes, cyberattacks, or other governmental or market responses, could lead to significant disruption of global energy supplies and increases in global energy prices, heighten inflationary pressures on our input costs and supply chain, adversely affect global supply chains, energy markets, commodity prices, currency exchange rates, financial markets and overall macroeconomic conditions, and adversely impact customer spending patterns in markets in which we operate. While we do *not* expect the impacts of conflict between the United States, Israel, and Iran to have a significant effect on our business, financial condition and results of operations, we are unable to predict the extent or nature of potential future impacts at this time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *25*

------

[**Table of Contents**](#toc)

***18.* Offerings of Common Stock**

On *September 15, 2025,* the Company entered into a Securities Purchase Agreement (the "Private Placement SPA") with Unusual Machines, Inc., a Nevada corporation ("Unusual Machines"), and Ondas Holdings Inc., a Nevada corporation ("Ondas," together with Unusual Machines, the "Private Placement Buyers"), pursuant to which the Private Placement Buyers agreed to purchase from the Company an aggregate of 1,600,000 shares of Class A Common Stock (the "Private Placement Securities") at a purchase price of $5.00 per share (the "Private Placement"). The Private Placement closed on *September 16, 2025* and the Company received aggregate proceeds from the Private Placement of $8.0 million, before deducting offering expenses of approximately $0.1 million paid by the Company. The Company intends to use the proceeds from the Private Placement to fund working capital and other general corporate purposes. The Private Placement SPA contains customary representations, warranties, covenants, conditions and indemnification obligations of the parties.

On *December 12, 2025,* we entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 7,750,000 shares of Common Stock, at a public offering price of $7.75 per share. Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriters a *30*-day option to purchase up to an additional 1,162,500 shares of Common Stock in the Offering at the public offering price. The Offering closed on *December 15, 2025,* for a total of 8,912,500 shares of Common Stock (including the 1,162,500 shares issuable pursuant to the Underwriter's *30*-day option), with net proceeds of $65.2 million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *26*

------

[**Table of Contents**](#toc)

**Item 2. Management**'**s Discussion and Analysis of Financial Condition and Results of Operations**

Management's Discussion and Analysis of Financial Condition and Results of Operations is designed to provide a reader of the financial statements with a narrative report on our financial condition, results of operations, and liquidity. This discussion and analysis should be read in conjunction with the attached unaudited Condensed Consolidated Financial Statements and notes thereto and our Annual Report on Form 10-K for the year ended June 30, 2025, including the audited Consolidated Financial Statements and notes thereto. The following discussion contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Our actual results could differ materially from those discussed in the forward-looking statements. Please also see the cautionary language at the beginning of this Quarterly Report on Form 10-Q regarding forward-looking statements.

**<u>Introduction</u>**

We were incorporated in Delaware in 1992 as the successor to LightPath Technologies Limited Partnership, a New Mexico limited partnership, formed in 1989, and its predecessor, Integrated Solar Technologies Corporation, a New Mexico corporation, formed in 1985. Today, LightPath is a global company with major facilities in the U.S., the People's Republic of China, and the Republic of Latvia.

Historically, we operated with a focus on optical component manufacturing, and specifically on our leadership position as a precision molded lens manufacturer for visual light applications. We expanded our addressable market with the acquisition of ISP, a manufacturer of infrared optical components, in December 2016. Since 2020, our strategy has been to move up the value chain by producing optical assemblies, modules and simple cameras. The acquisition of Visimid in 2023 and the acquisition of G5 Infrared in 2025 were completed to enhance our abilities on cameras and sensors and speed our movement up the value chain in line with our strategy of value-add infrared systems.

***Subsidiaries***

In November 2005, we formed LPOI, a wholly-owned subsidiary, located in Jiading, People's Republic of China, which was primarily engaged in sales and support functions. In December 2013, we formed LPOIZ, a wholly-owned subsidiary located in the New City district, of the Jiangsu province, of the People's Republic of China. LPOIZ's manufacturing facility serves as our primary manufacturing facility in China and provides a lower cost structure for production of larger volumes of optical components and assemblies. Effective February 28, 2023, the legal entities of LPOI and LPOIZ were merged, with LPOIZ as the surviving company.

In December 2016, we acquired ISP, and its wholly-owned subsidiary, ISP Latvia. ISP is a vertically-integrated manufacturer offering a full range of infrared products from custom infrared optical elements to catalog and high-performance lens assemblies. ISP's manufacturing operation is located at our corporate headquarters facility in Orlando, Florida (the "Orlando Facility"). ISP Latvia is a manufacturer of high precision optics and offers a full range of infrared products, including catalog and custom infrared optics. ISP Latvia's manufacturing facility is located in Riga, Latvia.

In July 2023, we acquired Visimid. Visimid is an engineering and design firm specializing in thermal imaging, night vision and internet of things applications. Visimid provides design and consulting services for U.S. Department of Defense contractors, commercial and industrial customers, and original equipment manufacturers for original new products. Visimid's core competency is developing and producing custom thermal and night vision cores. Visimid's facility is located in Plano, Texas.

In February 2025, we acquired G5 Infrared. G5 Infrared is a leading vertically-integrated manufacturer of high-performance infrared camera systems and imaging solutions, specializing in advanced thermal imaging technology and long-range mission-critical detection solutions. G5 Infrared's existing revenue and future growth pipeline are driven by established multi-year contracts and multiple defense programs of record in shipboard long-range surveillance, border security, and counter unmanned aerial systems ("C-UAS") systems, as well as recurring federal, naval, and law enforcement programs. Additionally, G5 Infrared is an industry-leading provider of cutting-edge advanced infrared coatings, including for materials such as LightPath's BlackDiamond ("BlackDiamond") glass. G5 Infrared operates from a state-of-the-art manufacturing facility in Hudson, New Hampshire. We believe that this acquisition strengthens LightPath's position as a leader in infrared imaging by expanding the Company's portfolio to include cooled infrared cameras. The combination of LightPath and G5 Infrared creates a more robust, vertically-integrated solutions provider.

In January 2026, we acquired the assets of Amorphous Materials, Inc. through our newly-formed, wholly-owned subsidiary, AML. AML specializes in infrared glass fabrication, and operates from a manufacturing facility in Garland, Texas. We believe that this acquisition further strengthens LightPath's position as a leader in infrared imaging by expanding our materials portfolio and glass fabrication capabilities.

For additional information, please refer to our Annual Report on Form 10-K for the year ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

***Product Groups***

We categorize our products into four product groups: (i) infrared components, (ii) visible components, (iii) assemblies and modules, and (iv) engineering services. G5 Infrared's revenue is generally derived from infrared components (including coating services) and assemblies and modules.

Our infrared product group is comprised of both molded and turned infrared lenses using a variety of infrared glass materials. This product group includes both conventional and CNC ground and polished lenses. This product group also includes revenue from sales of our BlackDiamond glass materials, the infrared materials offered by AML, and G5 Infrared's optical component and coating business. Advances in chalcogenide materials have enabled compression molding for mid-wave ("MWIR") and long-wave ("LWIR") optics in a process similar to precision molded lenses. Our molded infrared optics technology enables high performance, cost-effective infrared aspheric lenses that do not rely on traditional diamond turning or lengthy polishing methods. Utilizing precision molded aspheric optics significantly reduces the number of lenses required for typical thermal imaging systems and the cost to manufacture these lenses. Molding is an excellent alternative to traditional lens processing methods particularly where volume and repeatability is required.

Our visible components product group consists of visible precision molded optics with varying applications. Aspheric lenses are known for their optimal performance. Aspheric lenses simplify and shrink optical systems by replacing several conventional lenses. However, aspheric lenses can be difficult and costly to machine. Our glass molding technology enables the production of both low and high volumes of aspheric optics, while still maintaining the highest quality at an affordable price. Molding is the most consistent and economical way to produce aspheres and we have perfected this method to offer the most precise molded aspheric lenses available.

Between these two component product groups, we have the capability to manufacture lenses from very small (with diameters of a sub-millimeter) to over 300 millimeters, and with focal lengths from approximately 0.4 millimeters to over 2,000 millimeters. In addition, both product groups offer both catalog and custom designed optics.

Our assemblies and modules product group is comprised of both optical assemblies such as lens systems, and cameras, both in the form of camera modules and complete camera systems. Historically this product group also included optical fiber collimators and some visible lens assemblies, however those are now a very small part of our activity, making infrared cameras and assemblies the most dominant part of this group. Today, the majority of the revenue of this group is derived from cameras made in our Texas facility (uncooled camera systems and modules), cameras made in our New Hampshire facility (cooled cameras for long range surveillance and detection), and optical assemblies such as standard off the shelf lens assemblies, and custom lens assemblies, the latter of which are produced mainly in Orlando. This product group also includes revenue from camera repair services, primarily from G5 Infrared.

Our engineering services product group represents services we provide pursuant to product development agreements that we enter into with customers. Typically, customers approach us and request that we develop new products or applications utilizing our existing products to fit their particular needs or specifications. The purpose of those engineering services that we offer is not only to provide purely engineering services for a customer, but also to engineer new products which we later manufacture for the customer. The timing and extent of any such product development requests are unpredictable and outside of our control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

[**Table of Contents**](#toc)

***Growth Strategy***

Since our Chief Executive Officer, Mr. Sam Rubin, joined the Company in 2020, we have been developing a new strategy that is transitioning the Company from a pure component manufacturer to a supplier of imaging subsystems and systems. Our strategic direction, which is based on our core technological differentiators such as our BlackDiamond glass ("BlackDiamond") and proprietary molding technologies, significantly increases our value add to customers. This transition, which is occurring both organically and through acquisitions, such as the July 2023 acquisition of Visimid, the February 2025 acquisition of G5 Infrared, and the January 2026 acquisition of the assets of Amorphous Materials, Inc., is positioning the Company for significant growth and higher profitability in coming years. Each of these acquisitions has also added to our technological differentiators.

Understanding the shifts that are happening in the marketplace and the changes that come when a technology, like photonics, moves from being a specialty to being integrated into mainstream industries and applications, we redefined our strategic direction to provide our wide customer base with domain expertise in optics, and became their partner for the optical engine of their systems. In our view, as the use of photonics evolves, so do customer needs. The industry is transforming from a fragmented industry with a component oriented supply chain, into a solution-focused industry with the potential for partnerships for solution development and production. Over the last couple of years we have worked to align our organization to this strategy, and leverage our in-house domain expertise in photonics, knowledge and experience in advanced optical technologies, and the necessary manufacturing techniques and capabilities. We have been developing these partnerships by working closely with our customers throughout their design process, designing optical solutions that are tailored to their needs, often times using unique technologies that we own, and supplying the customer with a complete optical subsystem to be integrated into their product. Such an approach builds on our unique, value-added technologies that we currently own, such as infrared materials, optical molding, fabrication, system design, and proprietary manufacturing technologies, along with technologies that we acquired through the Visimid acquisition, such as video processing, and technologies from the G5 Infrared acquisition, such as long range imaging using cooled midwave cameras. Continually adding differentiating technologies is key to our strategy and we expect to continue to do so both organically and through acquisitions.

Examples of this strategic approach can be found in many of our recent new product lines. We refer to these as LightPath 2.0 and 3.0, as that symbolizes the evolution of the Company. LightPath 2.0 refers to our assemblies and LightPath 3.0 refers to our cameras and related subsystems and systems. Like any company, a successful implementation of a strategy depends heavily on differentiators. In our case, those differentiators mostly tend to be technologies and capabilities. Over the last few years we have worked to, and will continue to work to, add and evolve our differentiators. Some of our differentiators currently include our unique BlackDiamond materials, optical system design capabilities, glass molding technology, processing of thermal images, and long range imaging technologies. Examples of how those differentiators translate into revenue include our multispectral Mantis camera, our missile program with Lockheed Martin, our long range cameras for border patrol and C-UAS applications, and a number of other system and subsystem level products and programs that are enabled by these technologies. A recent example was our announcement of two G5 Infrared cameras that have been re-designed to eliminate Germanium from the bill of materials, leveraging the advantages of our BlackDiamond materials as alternative to Germanium.

The shift in strategy and product offerings also shifts the price range of our product portfolio and indirectly drives growth in and of itself. Historically, as a pure component Company, the average selling prices ("ASPs") of those products were measured in single dollars or tens of dollars, whereas with the development of our assemblies product line (i.e., LightPath 2.0), ASPs for those products are measured in hundreds of dollars. When we added cameras, subsystems and systems (i.e., LightPath 3.0), ASPs for those products are measured in tens of thousands, and sometimes hundreds of thousands of dollars. We expect this shift to start favorably impacting our financial results in future periods.

Further information about our strategic direction can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

[**Table of Contents**](#toc)

**<u>Results of Operations</u>**

**Revenue**

*Three Months ended March 31, 2026, compared to three months ended March 31, 2025*

Revenue for the third quarter of fiscal 2026 was approximately $19.1 million, an increase of approximately $10.0 million, or 109%, as compared to approximately $9.2 million in the same quarter of the prior fiscal year, primarily driven by increases in infrared components and assemblies and modules. While the G5 Infrared revenue was a significant contributor to the increase in revenue of infrared components and assemblies and modules for the third quarter of fiscal 2026, other revenue from infrared components and assemblies and modules also grew, as well as revenue from visible components. G5 Infrared revenue was included for approximately half of the third quarter of the prior fiscal year.

Revenue from infrared components was approximately $6.1 million in the third quarter of fiscal 2026, an increase of $2.5 million, or 69%, as compared to the same quarter of the prior fiscal year. Of this increase, approximately $0.9 million is due to an increase in G5 Infrared sales of coating services and components. The AML transaction, which closed during the third quarter of fiscal 2026, contributed approximately $1 million to the increase in sales of infrared components. The remaining $0.6 million increase in revenue is primarily due to an increase in sales to defense and industrial customers in Europe.

Revenue from the visible components product group for the third quarter of fiscal 2026 was $4.0 million, an increase of approximately $1.1 million, or 40%, as compared to the same quarter of the prior fiscal year. The increase was primarily driven by an increase in sales to industrial customers in the U.S., Europe and Asia.

Revenue from assemblies and modules was approximately $8.4 million in the third quarter of fiscal 2026, an increase of approximately $6.6 million, or 355%, as compared to the same quarter of the prior fiscal year. Of this increase, approximately $6.4 million is due to an increase in G5 Infrared sales of cameras and modules, including the previously announced program with a large global technology customer.

Revenue from engineering services decreased by approximately $0.2 million, or 29%, for the third quarter of fiscal 2026, as compared to the same quarter of the prior fiscal year. The third quarter of fiscal 2025 included non-recurring revenue from a space-related funded research contracts. Visimid's development contract with Lockheed Martin also contributed to the decrease, where the timing and dollar value of deliverables is not always consistent, which causes revenue for this product group to fluctuate from period to period. For the third quarter of fiscal 2026, the revenue recognized against this contract was less than in the third quarter of fiscal 2025.

*Nine months ended March 31, 2026, compared to nine months ended March 31, 2025*

Revenue for the first nine months of fiscal 2026 was approximately $50.6 million, an increase of approximately $25.6 million, or 102%, as compared to approximately $25.0 million in the same period of the prior fiscal year, primarily driven by increases in infrared components and assemblies and modules resulting from the addition of G5 Infrared revenue since acquisition. While the G5 Infrared revenue was a significant contributor to the increase in revenue of infrared components and assemblies and modules for the third quarter of fiscal 2026, other revenue from infrared components and assemblies and modules also grew, as well as revenue from visible components.

Revenue from infrared components was approximately $15.4 million in the first nine months of fiscal 2026, an increase of $6.1 million, or 65%, as compared to the same period of the prior fiscal year. Of this increase, approximately $2.7 million is due to an increase in G5 Infrared sales of coating services and components. AML, which was acquired during the third quarter of fiscal 2026, contributed approximately $1 million to the increase in sales of infrared components. The remaining $2.3 million increase in revenue from infrared components is primarily due to increases in sales to defense and industrial customers in Europe.

Revenue from the visible components product group for the first nine months of fiscal 2026 was $11.3 million, an increase of approximately $2.4 million, or 26%, as compared to the same period of the prior fiscal year. The increase was primarily driven by increases in sales to industrial customers the U.S., Europe and Asia.

Revenue from assemblies and modules was approximately $21.5 million in the first nine months of fiscal 2026, an increase of approximately $17.7 million, or 465%, as compared to the same period of the prior fiscal year. Of this increase, approximately $17.4 million is due to an increase in G5 Infrared sales of cameras and modules, including previously announced large programs.

Revenue from engineering services decreased by approximately $0.5 million, or 19%, for the first nine months of fiscal 2026, as compared to the same period of the prior fiscal year. This decrease was primarily driven by Visimid's development contract with Lockheed Martin, where the timing and dollar value of deliverables is not always consistent, which causes revenue for this product group to fluctuate from period to period. For the first nine months of fiscal 2026, the revenue recognized against this contract was less than in the same period of fiscal 2026, partially offset by a non-recurring engineering project for another defense customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

[**Table of Contents**](#toc)

**Gross Profit**

In the third quarter of fiscal 2026, gross profit was approximately $7.0 million, an increase of $5.7 million, or 161%, as compared to the same quarter of the prior fiscal year. Total cost of sales was approximately $12.2 million for the third quarter of fiscal 2026, compared to approximately $6.5 million for the same quarter of the prior fiscal year. Gross margin as a percentage of revenue was 36% for the third quarter of fiscal 2026, compared to 29% for the same quarter of the prior fiscal year. In the first nine months of fiscal 2026, gross profit was approximately $17.5 million, an increase of $10.0 million, or 135%, as compared to the same period of the prior fiscal year. Total cost of sales was approximately $33.1 million for the first nine months of fiscal 2026, compared to approximately $17.6 million for the same period of the prior fiscal year. Gross margin as a percentage of revenue was 35% for the first nine months of fiscal 2026, compared to 30% for the same period of the prior fiscal year. The increase in gross margin as a percentage of revenue is primarily driven by the increase in revenue from assemblies and modules, which generally have higher margins. In addition, gross margins for infrared products have improved due to a more favorable mix of customers and the resolution of certain manufacturing yield issues that negatively impacted prior periods.

**Selling, General and Administrative**

In the third quarter of fiscal 2026, SG&A costs were approximately $6.3 million, an increase of approximately $1.8 million, or 42%, as compared to approximately $4.4 million in the same quarter of the prior fiscal year. In the first nine months of fiscal 2026, SG&A costs were approximately $16.5 million, an increase of approximately $5.5 million, or 49%, as compared to approximately $11.1 million in the same period of the prior fiscal year. The increase in SG&A costs is partially due to the addition of G5 Infrared SG&A costs of $0.4 million and $2.4 million for the third quarter and first nine months of fiscal 2026, respectively. The AML transaction also added $0.3 million and $0.4 million in SG&A for the third quarter and first nine months of fiscal 2026, respectively, including acquisition costs. In addition, we have increased our sales and marketing spend to promote new products, including personnel costs, travel, advertising and tradeshows. We have also increased our spend on information technology to meet heightened security standards as required by our customers, and for acquisition integration projects. Our SG&A personnel costs have also increased due to filling certain vacant executive roles and accruing for incentive compensation plans for employees.

**New Product Development**

In the third quarter of fiscal 2026, new product development costs were approximately $1.0 million, an increase of $0.3 million, or 38%, as compared to the same quarter of the prior fiscal year. New product development costs increased with the addition of G5 Infrared product development costs, and other additional engineering personnel. These increases were partially offset by a decrease in outside services utilized for development projects, due to timing of such projects.

In the first nine months of fiscal 2026, new product development costs were approximately $2.7 million, an increase of approximately $0.7 million, or 33%, as compared to the same period of the prior fiscal year. This increase includes the addition of G5 Infrared product development costs, and other additional engineering personnel, as well as an increase in materials utilized for development projects, primarily for infrared cores and camera systems. These increases were partially offset by a decrease in outside services utilized for development projects, due to timing of such projects.

**Amortization of Intangibles**

Amortization of intangibles decreased by $0.3 million for the third quarter of fiscal 2026, as compared to the same quarter of the prior fiscal year, and increased by $0.1 million for the first nine months of fiscal 2026, as compared to the same period of the prior fiscal year. The decreases are driven by the reduction in amortization of intangible assets associated with prior acquisitions, partially offset by amortization of identifiable intangible assets associated with the acquisitions of G5 Infrared and AML.

**Other Income (Expense)**

Interest income, net, was approximately $0.3 million for the third quarter of fiscal 2026, as compared to interest expense, net, of $0.5 million for the same quarter of the prior fiscal year. For the first nine months of fiscal 2026, interest expense, net, was $0.3 million, as compared to $0.8 million for the same period of the prior fiscal year. The prior periods included interest and amortization of loan issuance costs associated with the Acquisition Notes, executed in February 2025, which replaced the Bridge Note, executed in August 2024. The Acquisition Notes were paid in full on December 31, 2025, following the Offering (as defined below) which generated net proceeds of $65.2 million. Much of our cash balance is now generating interest income, which is partially offset by the interest expense on equipment loans and finance leases.

Other expense, net, was approximately $0.03 million for the third quarter of fiscal 2026, as compared to other income, net, of $0.01 million for the same quarter of the prior fiscal year. Other expense, net was approximately $0.1 million for the first nine months of fiscal 2026, as compared to other income, net of $0.01 million for the same period of the prior fiscal year. Other expense or income, net, includes net gains and losses on foreign exchange transactions. We execute all foreign sales from our U.S. facilities and inter-company transactions in U.S. dollars, partially mitigating the impact of foreign currency fluctuations. Assets and liabilities denominated in non-U.S. currencies, primarily the Chinese Yuan and Euro, are translated at rates of exchange prevailing on the balance sheet date, and revenues and expenses are translated at average rates of exchange for the year.

**Income Taxes**

Income tax expense was approximately $0.1 million for both the third quarter of fiscal 2026 and 2025, and $0.2 million for both the first nine months of fiscal 2026 and 2025. Income tax expense for these periods is primarily related to income taxes from our operations in China, including withholding taxes on payments from LPOIZ to LightPath for administrative services rendered.

**Net Loss**

Net loss for the third quarter of fiscal 2026 was approximately $4.1 million, or $0.07 basic and diluted loss per share, compared to $3.6 million, or $0.09 basic and diluted loss per share, for the same quarter of the prior fiscal year. The increase in net loss of approximately $0.5 million for the third quarter of fiscal 2026, as compared to the same quarter of the prior fiscal year, was primarily attributable to the increased operating loss, which was largely driven by the change in fair value of acquisition liabilities for the earnout related to the acquisition of G5 Infrared.

Net loss for the first nine months of fiscal 2026 was approximately $16.4 million, or $0.33 basic and diluted loss per share, compared to $7.8 million, or $0.19 basic and diluted loss per share, for the same quarter of the prior fiscal year. The increase in net loss of approximately $8.6 million for the first nine months of fiscal 2026, as compared to the same period of the prior fiscal year, was primarily attributable to the increased operating loss, which was largely driven by the change in fair value of acquisition liabilities for the earnout related to the acquisition of G5 Infrared.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

[**Table of Contents**](#toc)

Weighted-average common shares outstanding for the third quarter of fiscal 2026 were 58,628,741, basic and diluted, compared to 41,363,643, basic and diluted, in the same quarter of fiscal 2025. Weighted-average common shares outstanding for the first nine months of fiscal 2026 were 49,572,872, basic and diluted, compared to 40,209,657, basic and diluted, in the first nine months of fiscal 2025. The increase in weighted-average basic common shares was due to: (i) the Common Stock issued in conjunction with the financing of the acquisition of G5 Infrared (refer to Note 4, *Acquisition of G5 Infrared*, in the Notes to the unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for additional information); (ii) the Private Placement (as defined below) of 1,600,000 shares of Common Stock which closed in September 2025; (iii) the Offering (as defined below) of 8,912,500 million shares of Common Stock which closed in December 2025; (iv) the shares of Common Stock issued in conjunction with the acquisitions of Visimid and AML; and (v) the issuance of shares of Common Stock underlying vested RSUs and RSAs. Potential dilutive common stock equivalents were excluded from the calculation of diluted shares for all periods presented, as their effects would have been anti-dilutive due to net losses in those periods.

**<u>Liquidity and Capital Resources</u>**

As of March 31, 2026, we had working capital of approximately $61.5 million and total cash and cash equivalents of approximately $55.2 million, of which, approximately 6% of our cash and cash equivalents was held by our foreign subsidiaries.

Cash and cash equivalents held by our foreign subsidiaries in China and Latvia were generated in-country as a result of foreign earnings. We routinely declare intercompany dividends to remit a portion of the earnings of our foreign subsidiaries to LightPath, as the U.S. parent company. It is still our intent to reinvest a significant portion of earnings generated by our foreign subsidiaries, however, we may also repatriate a portion of their earnings, and we accrue for these taxes on the portion of earnings that we intend to repatriate. We currently do not intend for our Latvian subsidiary to declare intercompany dividends.

In China, before any funds can be repatriated, the retained earnings of the legal entity must equal at least 50% of the registered capital. As of March 31, 2026, LPOIZ had approximately $0.5 million available for repatriation, based on earnings accumulated through December 31, 2025, the end of the most recent statutory tax year, that remained undistributed as of March 31, 2026.

As of March 31, 2026, loans payable consists of one third-party equipment loan. The Acquisition Notes and one third-party equipment loan were paid in full during the three months ended December 31, 2025. See Note 14, *Loans Payable*, in the unaudited Condensed Consolidated Financial Statements, for further information.

On February 18, 2025, we announced the closing of the acquisition of G5 Infrared and the related financing, including the issuance of shares of Series G Convertible Preferred Stock. For additional information, refer to Note 4, *Acquisition of G5 Infrared*, in the accompanying unaudited Condensed Consolidated Financial Statements.

On September 15, 2025, we entered into a Securities Purchase Agreement (the "Private Placement SPA") with Unusual Machines, Inc., a Nevada corporation ("Unusual Machines"), and Ondas Holdings Inc., a Nevada corporation ("Ondas," together with Unusual Machines, the "Private Placement Buyers"), pursuant to which the Private Placement Buyers agreed to purchase from the Company an aggregate of 1,600,000 shares of Common Stock (the "Private Placement Securities") at a purchase price of $5.00 per share (the "Private Placement"). The Private Placement closed on September 16, 2025 and the Company received aggregate proceeds from the Private Placement of $8.0 million, before deducting offering expenses of approximately $0.1 million payable by the Company. The Company intends to use the proceeds from the Private Placement to fund working capital and other general corporate purposes. The Private Placement SPA contains customary representations, warranties, covenants, conditions and indemnification obligations of the parties.

On December 12, 2025, we entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 7,750,000 shares of Common Stock, at a public offering price of $7.75 per share. Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriters a 30-day option to purchase up to an additional 1,162,500 shares of Common Stock in the Offering at the public offering price, which the Underwriters exercised in full concurrent with the closing of the Offering on December 15, 2025.

There are a number of factors that could result in the need to raise additional funds, including a decline in revenue or a lack of anticipated sales growth, increased material costs, increased labor costs, planned production efficiency improvements not being realized, increases in property, casualty, benefit and liability insurance premiums, and increases in other costs. In addition, we may identify opportunities for additional acquisitions and other strategic transactions to expand and further enhance our business that may require that we raise additional capital should we elect to pursue any of such transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

------

[**Table of Contents**](#toc)

*Cash Flows* – *Operating:*

Cash used in operations was approximately $5.1 million for the first nine months of fiscal 2026, compared to approximately $5.7 million for the same period of the prior fiscal year. Cash used in operations for the first nine months of fiscal 2026 was primarily due to the following: (i) payment of the first earnout payment for the acquisition of G5 Infrared, of which $3.8 million was classified in operating activities, representing the amount in excess of the contingent consideration liability recognized as of the acquisition date; and (ii) investments in working capital of $2.7 million, largely driven by supplier prepayments for critical materials with long lead times. The net loss for the first nine months of fiscal 2026 was more than offset by non-cash items such as the change in fair value of acquisition liabilities, and stock compensation. Cash used in operations for the first nine months of fiscal 2025 was driven by the net loss, which was not fully offset by non-cash items, coupled with net investments in working capital of $1.9 million.

*Cash Flows* – *Investing:*

During the first nine months of fiscal 2026, we expended approximately $1.9 million in investments in capital equipment, compared to approximately $0.6 million in the same period of the prior fiscal year. In the third quarter of fiscal 2026, we expended $7.0 million for the AML acquisition, as disclosed in Note 3, *Acquisition of Amorphous Materials*, in the unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q. In the third quarter of fiscal 2025, we expended $20.3 million to acquire G5 Infrared, as disclosed in Note 4, *Acquisition of G5 Infrared*, in the unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

*Cash Flows* – *Financings:* 

Net cash provided by financing activities was approximately $64.0 million for the first nine months of fiscal 2026, compared to approximately $29.6 million in the same period of the prior fiscal year. Cash provided by financing activities for the first nine months of fiscal 2026 reflects the proceeds of $65.3 million from the Offering and $7.9 million from the Private Placement, offset by approximately $5.6 million in principal payments on our loans and finance leases, and $3.5 million for the first earnout payment for the acquisition of G5 Infrared, representing the amount of the contingent consideration liability recognized as of the acquisition date. Cash provided by financing activities for the first nine months of fiscal 2025 primarily reflects the Acquisition Financing of $27.0 million, net of financing costs and the Bridge Note conversion, plus $2.7 million in net proceeds from the Bridge Note, offset by approximately $0.3 million in principal payments on our loans and finance leases and $0.1 million for the final cash payment related to the acquisition of Visimid.

**<u>Critical Accounting Policies and Estimates</u>**

There have been no material changes to our critical accounting policies and estimates during the nine months ended March 31, 2026 from those disclosed in Item 7. *Management*'*s Discussion and Analysis of Financial Condition and Results of Operations*, of our Annual Report on Form 10-K for the year ended June 30, 2025.

**<u>How We Operate</u>**

We have continuing sales of two basic types: sales of standard product configurations and sales of customized products or products developed specifically for a certain customer. In this latter type of business, we work with customers to help them determine optical specifications and then create certain optical designs for them, including complex multi-component, optical system or sub-system designs that we call "engineered solutions." This is followed by "sampling" or prototyping small numbers of the product for the customers' test and evaluation. Thereafter, should a customer conclude that our specification or design is the best solution to their product need; we negotiate and "win" a contract (sometimes called a "design win") – whether of a "blanket purchase order" type or a supply agreement. The strategy is to create an annuity revenue stream that makes the best use of our production capacity and longer-term revenue planning, as compared to the turns business, which is unpredictable and uneven. A key business objective is to convert as much of our business to the design win and annuity model as is possible. We face several challenges in doing so:

• Maintaining an optical design and new product sampling capability, including a high-quality and responsive optical design engineering staff, opto-mechanical engineering, and all related disciplines;

• The fact that as our customers take products of this nature into higher volume, commercial production they begin to work seriously to reduce costs – which may lead them to turn to larger producers, domestic or overseas, even if sacrificing quality; and

• Our small business mass means that we can only offer a moderate amount of total productive capacity before we reach financial constraints imposed by the need to make additional capital expenditures – in other words, because of our limited cash resources and cash flow, we may not be able to service every opportunity that presents itself in our markets without arranging for such additional capital expenditures.

Despite these challenges to winning more "annuity" business, we nevertheless believe we can be successful in procuring this business because of our unique capabilities in optical design engineering that we make available on the market to our current and potential customers looking for specific solutions to their needs. Additionally, we believe that we offer value to some customers as a source of supply in the U.S. should they be unwilling to commit to purchase their supply of critical component(s) from foreign sources. For information regarding revenue recognition related to our various revenue streams, refer to *Critical Accounting Policies and Estimates* in our Annual Report on Form 10-K dated June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33

------

[**Table of Contents**](#toc)

*Our Key Performance Indicators:*

Typically, on a weekly basis, management reviews a number of performance indicators, both qualitative and quantitative. These indicators change from time to time as the opportunities and challenges in the business change. These indicators are used to determine tactical operating actions and changes. We believe that our non-financial production indicators, such as those noted, are proprietary information.

Financial indicators that are considered key and reviewed regularly are as follows:

● Sales backlog;

● Revenue by product group;

● EBITDA and Adjusted EBITDA; and

● Other key indicators.

These indicators are also used to determine tactical operating actions and changes and are discussed in more detail below. Management continues to evaluate these key indicators as we refine our strategic plan to determine whether any changes or updates to our key indicators are warranted.

***<u>Sales Backlog</u>***

We believe sales growth has been and continues to be a key indicator of success. Our best view into the efficacy of our sales efforts is in our "order book." Our order book equates to sales "backlog." It has a quantitative and a qualitative aspect: quantitatively, our backlog's prospective dollar value and qualitatively, what percent of the backlog is scheduled by the customer for date-certain delivery. We monitor and evaluate our total backlog, which includes all firm orders requested by a customer that are reasonably believed to remain in the backlog and be converted into revenues. This includes customer purchase orders and may include amounts under supply contracts if they meet the aforementioned criteria.

Our total backlog at March 31, 2026 was approximately $110.6 million, an increase of 196%, as compared to $37.4 million as of June 30, 2025. Backlog change rates for the last five fiscal quarters are:

---

| | | | |
|:---|:---|:---|:---|
|  | **Total Backlog** | **Change From** | **Change From** |
| **Quarter** | **(in thousands)** | **Prior Year End** | **Prior Quarter End** |
| **Q3 2025** | $27423 | 42% | 39% |
| **Q4 2025** | $37390 | 94% | 36% |
| **Q1 2026** | $86043 | 130% | 130% |
| **Q2 2026** | $97837 | 162% | 14% |
| **Q3 2026** | $110557 | 196% | 13% |

---

The acquisition of G5 Infrared added $5.6 million of backlog, as of the Acquisition Date, during the third quarter of fiscal 2025. As of March 31, 2026, backlog for G5 Infrared products was $80.6 million, compared to $16.6 million as of June 30, 2025. Included in the increase from June 30, 2025 to March 31, 2026 are approximately $58.0 million in orders from a leading global technology customer for advanced infrared camera systems expected to ship in calendar year 2026 and 2027, as well as several other multi-million dollar orders from other customers. In addition to these G5 Infrared orders, LightPath orders contributed approximately $8.1 million to the increase in backlog during the first nine months of fiscal 2026, primarily for infrared components. The acquisition of AML also added backlog of $1.1 million as of March 31, 2026. During the first nine months of fiscal 2026, we received a significant contract renewal for advanced infrared optics for a critical international military program. The timing of multi-year contract renewals are not always consistent and, thus, backlog levels may increase substantially when annual and multi-year orders are received, and decrease as shipments are made against these orders. We anticipate that our existing annual and multi-year contracts will be renewed in future quarters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34

------

[**Table of Contents**](#toc)

Markets continue to experience growing demand for infrared products used in the industrial, defense, security and first responder sectors. Demand for infrared products continues to be fueled by interest in lenses made with our BD6 glass and our new BDNL materials. With the global supply of germanium concentrated in Russia and China, recent global events and increases in restrictions on the sourcing of these materials are generating renewed interest in germanium alternatives such as our proprietary BlackDiamond materials, and other materials we are currently developing under an exclusive license with the Naval Research Lab. The acquisition of AML further expands our infrared glass portfolio.

As we have outlined in our strategic direction, we do not expect to see significant growth in our visible components product group in the near future. Competition in that product line has grown substantially over the last few years, and some of our new molding capabilities and technologies such as free-form molded optics, might take longer than anticipated to reach full commercialization, depending on economic conditions and technology trends in the area of AR\VR.

In addition, order bookings for both visible and infrared components and assemblies continue to be slow in China. Domestic sales in China have also been adversely impacted by the economic downturn in China, which continues to negatively impact revenue and bookings in that region.

***<u>Revenue by Product Group</u>***

The following table sets forth revenue for our four product groups for the three and nine-month periods ended March 31, 2026 and 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |  |  |
|  | **Three Months Ended** | **Three Months Ended** |  | **Nine Months Ended** | **Nine Months Ended** |  |
|  | **March 31,** | **March 31,** | **Quarter** | **March 31,** | **March 31,** | **Year-to-Date** |
|  | **2026** | **2025** | **% Change** | **2026** | **2025** | **% Change** |
| **Revenue** |  |  |  |  |  |  |
| Infrared components | $6147583 | $3640517 | 69% | $15423577 | $9363477 | 65% |
| Visible components | 3971593 | 2838346 | 40% | 11254273 | 8901076 | 26% |
| Assemblies and modules | 8434403 | 1852482 | 355% | 21504936 | 3803364 | 465% |
| Engineering services | 596235 | 836282 | (29)% | 2376961 | 2924920 | (19)% |
| Total revenue | $19149814 | $9167627 | 109% | $50559747 | $24992837 | 102% |

---

**Three months ended March 31, 2026**

Our revenue increased by 109% in the third quarter of fiscal 2026 compared to the same quarter of the prior fiscal year, primarily driven by increases in infrared components and assemblies and modules. While the addition of G5 Infrared revenue since acquisition was a significant contributor to these product groups, other revenue from these product groups also grew, as well as revenue from visible components. Note that G5 Infrared revenue was included for approximately half of the third quarter of the prior fiscal year.

Revenue generated by the infrared components product group for the third quarter of fiscal year 2026 was $6.1 million, an increase of 69%, as compared to the same quarter of the prior fiscal year. Of this increase, approximately $0.9 million is due to an increase in G5 Infrared sales of coating services and components. AML, which was acquired during the third quarter of fiscal 2026, contributed approximately $1.0 million to the increase in sales of infrared components. The remaining $0.6 million increase in revenue is primarily due to an increase in sales to defense and industrial customers in Europe.

Revenue from the visible components product group for the third quarter of fiscal year 2026 was $4.0 million, an increase of 40%, as compared to the same quarter of the prior fiscal year. The increase was primarily driven by increases in sales to industrial customers in the U.S., Europe and Asia. Although we do not expect significant growth in visible components revenue over the long term, demand has trended up in fiscal 2026 to date.

Revenue from assemblies and modules increased by $6.6 million, or 355%, for the third quarter of fiscal 2026, as compared to the same quarter of the prior fiscal year. Of this increase, approximately $6.4 million is due to an increase in G5 Infrared sales of cameras and modules, including the previously announced program with a large global technology customer. Based on our backlog, we expect continued revenue growth for this product group.

Revenue from engineering services decreased by $0.2 million for the third quarter of fiscal 2026, as compared to the same quarter of the prior fiscal year. The third quarter of fiscal 2025 included non-recurring revenue from a space-related funded research contracts. Visimid's development contract with Lockheed Martin also contributed to the decrease, as the timing and dollar value of deliverables is not always consistent, which causes revenue for this product group to fluctuate from period to period. For the third quarter of fiscal 2026, the revenue recognized against this contract was less than in the third quarter of fiscal 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

[**Table of Contents**](#toc)

**Nine months ended March 31, 2026**

Our revenue increased by 102% in the first nine months of fiscal 2026 compared to the same period of the prior fiscal year, primarily driven by increases in infrared components and assemblies and modules. While the addition of G5 Infrared revenue since acquisition was a significant contributor to these product groups, other revenue from these product groups also grew, as well as revenue from visible components.

Revenue generated by the infrared components product group for the first nine months of fiscal year 2026 was $15.4 million, an increase of 65%, as compared to the same period of the prior fiscal year. Of this increase, approximately $2.7 million is due to an increase in G5 Infrared sales of coating services and components. AML, which was acquired during the third quarter of fiscal 2026, contributed approximately $1.0 million to the increase in sales of infrared components. The remaining $2.3 million increase in revenue from infrared components is primarily due to increases in sales to defense and industrial customers in the U.S. and in Europe, which has been a consistent trend for fiscal 2026 to date.

Revenue from the visible components product group for the first nine months of fiscal year 2026 was $11.3 million, an increase of 26%, as compared to the same period of the prior fiscal year. The increase was primarily driven by increases in sales to industrial customers in Asia, as well as in the U.S and Europe. Although we do not expect significant growth in visible components revenue over the long term, demand has trended up in fiscal 2026 to date.

Revenue from assemblies and modules increased by $17.7 million, or 465%, for the first nine months of fiscal 2026, as compared to the same period of the prior fiscal year, driven by G5 Infrared sales of cameras and modules. Based on our backlog, we expect continued revenue growth for this product group.

Revenue from engineering services decreased $0.5 million, for the first nine months of fiscal 2026, as compared to the same period of the prior fiscal year. This decrease was primarily driven by Visimid's development contract with Lockheed Martin, where the timing and dollar value of deliverables is not always consistent, which causes revenue for this product group to fluctuate from period to period. For the first nine months of fiscal 2026, the revenue recognized against this contract was less than in the first nine months of fiscal 2026. The third quarter of fiscal 2025 included non-recurring revenue from a space-related funded research contracts. These decreases were partially offset by non-recurring engineering revenue from another defense customer.

***<u>Other Key Indicators</u>***

Other key indicators include various qualitative and quantitative operating metrics. These indicators change from time to time as the opportunities and challenges in the business change. They are mostly non-financial indicators, such as evaluating the pipeline of sales opportunities, on time delivery trends, production yield rates by major product line, and the output and yield data from significant intermediary manufacturing processes that support the production of the finished shippable product. The data from these reports is used to determine tactical operating actions and changes. Management also assesses business performance and makes business decisions regarding our operations using certain non-GAAP measures. These non-GAAP measures are described in more detail below under the heading "Non-GAAP Financial Measures."

**<u>Non-GAAP Financial Measures</u>**

We report our historical results in accordance with GAAP; however, our management also assesses business performance and makes business decisions regarding our operations using certain non-GAAP financial measures. We believe these non-GAAP financial measures provide useful information to management and investors that is supplementary to our financial condition and results of operations computed in accordance with GAAP; however, we acknowledge that our non-GAAP financial measures have a number of limitations. As such, you should not view these disclosures as a substitute for results determined in accordance with GAAP, and they are not necessarily comparable to non-GAAP financial measures that other companies use.

*EBITDA and Adjusted EBITDA*

EBITDA and Adjusted EBITDA are non-GAAP financial measures used by management, lenders, and certain investors as a supplemental measure in the evaluation of some aspects of a corporation's financial position and core operating performance. Investors sometimes use EBITDA, as it allows for some level of comparability of profitability trends between those businesses differing as to capital structure and capital intensity by removing the impacts of depreciation and amortization. EBITDA also does not include changes in major working capital items, such as receivables, inventory and payables, which can also indicate a significant need for, or source of, cash. Since decisions regarding capital investment and financing and changes in working capital components can have a significant impact on cash flow, EBITDA is not necessarily a good indicator of a business's cash flows. We use EBITDA for evaluating the relative underlying performance of our core operations and for planning purposes. We calculate EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation and amortization, thus the term "Earnings Before Interest, Taxes, Depreciation and Amortization" and the acronym "EBITDA."

We also calculate an adjusted EBITDA, which excludes, as applicable: (1) stock compensation expenses; (2) the loss on extinguishment of debt; (3) the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to the warrants; (4) the effect of non-cash income or expenses associated with the fair value adjustments related to the acquisition earnout liabilities; (5) acquisition costs, including legal fees and due diligence; and (6) the effect of foreign exchange gains or losses. Management uses adjusted EBITDA to evaluate our underlying operating performance and for planning and forecasting future business operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

[**Table of Contents**](#toc)

We believe EBITDA and Adjusted EBITDA are helpful for investors to better understand our underlying business operations. The following table adjusts net loss to EBITDA and Adjusted EBITDA for the three and nine months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **March 31,** | **March 31,** | **March 31,** | **March 31,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Net loss | $(4106287) | $(3582460) | $(16404698) | $(7817202) |
| Depreciation and amortization | 1263005 | 1463150 | 3717691 | 3356752 |
| Income tax provision | 91390 | 100031 | 203216 | 160192 |
| Interest (income) expense | (271641) | 486833 | 282235 | 805246 |
| EBITDA | $(3023533) | $(1532446) | $(12201556) | $(3495012) |
| Stock-based compensation | 562966 | 239134 | 1261577 | 745155 |
| Loss on extinguishment of debt |  | 418502 | 506280 | 418502 |
| Change in fair value of warrant liability |  | (870554) |  | (870554) |
| Change in fair value of acquisition earnout liabilities | 3393000 | 130445 | 12234529 | 130445 |
| Acquisition costs | 145539 |  | 220175 |  |
| Foreign exchange loss (gain) | 59195 | (7627) | 115264 | (11701) |
| Adjusted EBITDA | $1137167 | $(1622546) | $2136269 | $(3083165) |
| % of revenue | 6% | -18% | 4% | -12% |

---

Our adjusted EBITDA for the quarter ended March 31, 2026 was approximately $1.1 million, compared to a loss of $1.6 million for the same quarter of the prior fiscal year. The increase in adjusted EBITDA in the third quarter of fiscal 2026 was primarily attributable to the increase in gross profit, driven by higher sales, partially offset by increased SG&A and new product development costs.

Our adjusted EBITDA for the nine months ended March 31, 2026 was approximately $2.1, compared to a loss of $3.1 million for the same period of the prior fiscal year. The increase in adjusted EBITDA in the first nine months of fiscal 2026 was primarily attributable to the increase in gross profit, driven by higher sales, partially offset by increased SG&A and new product development costs.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Because we are allowed to comply with the disclosure obligations applicable to a "smaller reporting company," as defined by Rule 12b-2 of the Exchange Act, with respect to this Quarterly Report on Form 10-Q, we are not required to provide the information required by this Item.

**Item 4. Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of March 31, 2026, the end of the period covered by this Quarterly Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026 in reporting on a timely basis information required to be disclosed by us in the reports we file or submit under the Exchange Act.

There have not been any significant changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the nine months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

[**Table of Contents**](#toc)

**<u>PART II OTHER INFORMATION</u>**

**Item 1. Legal Proceedings**

The Company is subject, from time to time, to various legal proceedings that are incidental to the conduct of its business. The Company is not involved in any pending legal proceeding that it believes would reasonably be expected to have a material adverse effect on its financial condition or results of operations.

**Item 1A. Risk Factors**

Our business, operations, and financial condition are subject to various risks and uncertainties. The risk factors described in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K, for the year ended June 30, 2025, should be carefully considered, together with the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and in our other filings with the SEC in connection with evaluating us, our business, and the forward-looking statements contained in this Quarterly Report on Form 10-Q. During the nine months ended March 31, 2026, there have been no material changes from the risk factors previously disclosed under Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K, for the year ended June 30, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Other than as set forth below, information required by Item 701 of Regulation S-K as to all unregistered sales of equity securities of the Company during the period covered by this Quarterly Report has previously been included in Current Reports on Form 8-K filed with the SEC.

On or about January 2, 2026 and April 1, 2026, the Company awarded 1,000 and 1,077 shares, respectively, of restricted stock to a consultant for services rendered with respect to investor relations services. Such shares of restricted stock vested immediately. The Company relied upon the exemption from the registration requirements of the Securities Act, provided by Rule 506(b) of Regulation D and/or Section 4(a)(2) under the Securities Act for such issuance.

**Item 3. Defaults Upon Senior Securities**

None

**Item 4. Mine Safety Disclosures**

Not applicable

**Item *5.* Other Information**

(a) On *March 23, 2026 (*the "Grant Date"), the Company's Board of Directors approved equity awards to Shmuel Rubin, the Company's Chief Executive Officer, and Albert Miranda, the Company's Chief Financial Officer, under the Company's *2018* Stock and Incentive Compensation Plan (the "Plan").

*Restricted Stock Unit Awards* 

Pursuant to these approvals, (i) Mr. Rubin received an award of *375,000* restricted stock units and (ii) Mr. Miranda received an award of *75,000* restricted stock units. The restricted stock units vest in *three* equal annual installments, subject to continued service through the applicable vesting dates.

*Option Awards* 

Pursuant to these approvals, (i) Mr. Rubin received an option to purchase up to a maximum of *2,550,000* shares of Common Stock that could be earned over a *five*-year performance period following the Grant Date and (ii) Mr. Miranda received an option to purchase up to a maximum of *425,000* shares of Common Stock that could be earned over a *three*-year performance period following the Grant Date, each subject to the achievement of certain performance targets set forth in the applicable award agreements. Such awards are intended to align management's incentives with the creation of long-term stockholder value and to incentivize the achievement of extraordinary growth in the Company's revenue and operating profitability relative to the Company's historical growth rates. The Company determined that structuring the award with performance-based vesting conditions tied to substantial increases in revenue and adjusted EBITDA growth appropriately links potential realizable value to the Company's financial performance and stockholder returns.

The option award will vest, if at all, in tranches based on the achievement of specified revenue and adjusted EBITDA targets at multiple levels, with vesting at each level conditioned on the Company satisfying both applicable revenue and adjusted EBITDA criteria. Vesting begins only upon the attainment of a threshold that reflects a substantial multiple of the Company's current revenue and a corresponding meaningful increase in adjusted EBITDA, with only a small portion of the maximum option amount eligible to vest at such initial level. The vast majority of the award is conditioned on the achievement of significantly higher performance thresholds.

The stock options have an exercise price of *$10.53* per share and have a term of *10* years from the date of grant.

The awards are subject to the terms of the Plan and the applicable award agreements, including provisions regarding termination of service, change in control, and other customary terms.

The foregoing summary of awards are subject to, and qualified in their entirety by, the full text each of the restricted stock unit award agreement and option award agreement, the full text of the form of award agreements incorporated herein by reference.

(c) During the *nine* months ended *March 31, 2026*, no director or officer of the Company adopted or terminated a "Rule *10b5*-*1* trading arrangement" or "non-Rule *10b5*-*1* trading arrangement," as each term is defined in Item *408*(a) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

[**Table of Contents**](#toc)

**Item 6. Exhibits**

The following exhibits are filed herewith as a part of this report.

---

| | |
|:---|:---|
| **Exhibit Number**  | **Description** |
| [10.1](http://www.sec.gov/Archives/edgar/data/889971/000143774926001904/ex_911153.htm) | [Asset Purchase Agreement, dated January 20, 2026, by and among LightPath Technologies, Inc., Amorphous Materials, LLC, a Delaware limited liability company, Amorphous Materials, Inc., a Texas corporation and other parties thereto, which was filed as Exhibit 10.1 to our Current Report on Form 8-K (File No: 000-2758) filed with the Securities and Exchange Commission on January 23, 2026, and is incorporated herein by reference thereto.](http://www.sec.gov/Archives/edgar/data/889971/000143774926001904/ex_911153.htm) |
| [10.2\*](ex_956261.htm) | [Form of Restricted Stock Unit Agreement](ex_956261.htm) |
| [10.3\*](ex_956266.htm) | [Form of Stock Option Award Agreement](ex_956266.htm) |
| [31.1\*](ex_922750.htm) | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934](ex_922750.htm) |
| [31.2\*](ex_922751.htm) | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934](ex_922751.htm) |
| [32.1\*\*](ex_922752.htm) | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 of Chapter 63 of Title 18 of the United States Code](ex_922752.htm) |
| [32.2\*\*](ex_922753.htm) | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 of Chapter 63 of Title 18 of the United States Code](ex_922753.htm) |
| 101.INS | Inline XBRL Instance Document \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document \* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document \* |
| 101.PRE | Inline XBRL Taxonomy Presentation Linkbase Document \* |
| 104 | Cover Page Interactive Data File – formatted in Inline XBRL and contained in Exhibit 101 \* |

---

\*filed herewith

\*\*furnished, not filed

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **LIGHTPATH TECHNOLOGIES, INC.** | **LIGHTPATH TECHNOLOGIES, INC.** |
| Date: <u>May 7, 2026</u>  | By:  | /s/ Shmuel Rubin  |
|  |  | *Shmuel Rubin* |
|  |  | *President and Chief Executive Officer* |
| Date: <u>May 7, 2026</u> | By: | /s/ Albert Miranda |
|  |  | *Albert Miranda* |
|  |  | *Chief Financial Officer* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

## Exhibit 10.2

Exhibit 10.2

**<u>LightPath Technologies, Inc.</u>**

**<u>2018 Stock and Incentive Compensation Plan (</u>**<u>"</u>**<u>Plan</u>**<u>"</u>**<u>)</u>**

**<u>Restricted Stock Unit Agreement</u>**

This **RESTRICTED STOCK UNIT AGREEMENT** is entered into as of [DATE] (the "Grant Date") by and between LIGHTPATH TECHNOLOGIES, INC., a Delaware corporation (the "Company"), and the UNDERSIGNED EMPLOYEE (the "Employee").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **<u>Award of Restricted Stock Units</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Number of Restricted Stock Units</u>**. Subject to the terms and conditions of this Agreement and of the Plan, the Company hereby grants to the Employee [###] Stock Units, each being equivalent to one Share as provided in Section 12(a)(i) of the Plan (the "Stock Units"). This grant of Stock Units is made as consideration for the services to be rendered by the Employee to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Grant of Stock Units</u>**. The Stock Units will be granted upon acceptance of this Agreement by the Employee and the Shares underlying this Award shall be issued upon satisfaction of the conditions of this Agreement. The Stock Units shall be credited to a separate account maintained for the Employee on the books and records of the Company. All amounts so credited shall continue for all purposes to be part of the general assets of the Company. The number of Stock Units is subject to adjustment and modification as provided in the Plan. Accordingly, the total number of Stock Units granted pursuant to this Agreement means, at any relevant time, the number of Stock Units set forth in (a), above, as such number shall then have been adjusted pursuant to the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **<u>Plan Incorporated</u>**. The Employee acknowledges receipt of a copy of the Plan and agrees that this award of Stock Units is subject to all of the terms and conditions set forth in the Plan, including future amendments thereto, if any, which are incorporated herein by reference as a part of this Agreement. Unless defined in this Agreement, capitalized terms shall be as defined in the Plan. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall prevail and control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>Vesting and Payment</u>**. The Employee hereby accepts the Stock Units when granted and agrees with respect thereto as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Forfeiture Restrictions</u>**. The Stock Units may not be sold, assigned, pledged, exchanged, hypothecated, or otherwise transferred, encumbered or disposed of to the extent then subject to the Forfeiture Restrictions (as defined below). Any purported sale, assignment, pledge, exchange transfer, or other disposition or encumbrance of the Stock Units in violation of this Agreement shall be null and void. The Forfeiture Restrictions shall lapse on the third (3<sup>rd</sup>) anniversary of the Grant Date (the "Vesting Date"). In the event of the Employee's Termination of Employment by the Company or a Subsidiary for any reason prior to the Vesting Date, the Employee shall forfeit all Stock Units, except as otherwise provided herein or in Sections 13(c) and 15(b) of the Plan. The prohibition against transfer and the obligation to forfeit Stock Units upon Termination of Employment before the Stock Units vest are herein referred to as "Forfeiture Restrictions." The Forfeiture Restrictions shall be binding upon and enforceable against any transferee of Stock Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Payment</u>**. A certificate evidencing the Shares underlying each vested Stock Unit shall be issued by the Company in the Employee's name on the Vesting Date, or as soon as administratively practicable thereafter and within the same calendar year. Until the Shares are issued to the Employee, the Employee shall have no voting rights and no right to receive dividends or dividend equivalents with respect to the Shares. Notwithstanding any provision of this Agreement to the contrary, the issuance or delivery of any Shares may be postponed for such period as may be required to comply with applicable requirements of any national securities exchange or any requirements under any law or regulation applicable to the issuance or delivery of such shares in compliance with Section 409A of the Code. The Company shall not be obligated to issue or deliver any Shares if the issuance or delivery thereof constitutes a violation of any provision of any law or of any regulation of any governmental authority or any national securities exchange on which the Shares are listed. In addition, the delivery of the Shares may also be delayed in connection with a deferral election made by the Employee in accordance with procedures established by the Company with respect to same. The Company may, in its sole discretion, permit the deferral of delivery of Shares in accordance with requirements it establishes in compliance with the Plan and Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>Tax Liability and Withholding</u>**. The Employee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Employee pursuant to the Plan or otherwise, the amount of any Tax-Related Items (as defined below) in respect of the Stock Units and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment of such Tax-Related Items. The Committee may permit the Employee to satisfy any federal, state, or local tax withholding obligation by any of the following means, or by a combination of such means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) tendering a cash payment or requesting the withholding to be made from other cash compensation due to the Employee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) authorizing the Company to withhold Shares from those otherwise issuable or deliverable to the Employee as a result of the vesting of the Stock Units, provided, however, that no Shares shall be withheld with a value exceeding the maximum amount of tax required to be withheld by law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) delivering to the Company previously owned and unencumbered Shares.

Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (the "Tax-Related Items"), the ultimate liability for all Tax-Related Items is and remains the Employee's responsibility and the Company makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or settlement of the Stock Units or the subsequent sale of any Shares; and does not commit to structure the Stock Units to reduce or eliminate the Employee's liability for Tax-Related Items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **<u>Status of Shares</u>**. The Employee agrees that the Shares will not be sold or otherwise disposed of in any manner that would constitute a violation of any applicable federal or state securities laws. The Employee also agrees (i) that the certificates representing the Shares may bear such legend or legends as the Company deems appropriate in order to assure compliance with applicable securities laws or Company policies, (ii) that the Company may refuse to register the transfer of Shares on the stock transfer records of the Company if such proposed transfer would, in the opinion of counsel satisfactory to the Company, constitute a violation of any applicable securities law, and (iii) that the Company may give related instructions to its transfer agent, if any, to stop registration of the transfer of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Termination of Employment</u>**. For purposes of this Agreement, the Employee shall be considered to be in the active service of the Company as long as the Employee remains an employee of the Company or a parent or subsidiary corporation (as defined in Section 424 of the Code) of the Company. Any question as to whether and when there has been a Termination of Employment, and the cause of such termination, shall be determined by the Committee, or its delegate, as appropriate, and its determination shall be final and binding on all parties. Neither the Plan nor this Agreement shall confer upon the Employee any right to be retained in any position, as an Employee or otherwise, of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Employee's employment at any time, with or without Cause. Notwithstanding the foregoing, the Employee shall be considered to no longer be in the active service of the Company as of the date the Employee has a "separation from service" as defined in Treas. Reg. Section 1.409A-1(h) with respect to any Stock Unit that has been deferred for delivery to a year later than the year the Forfeiture Restrictions lapse.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>Committee</u>**<u>'</u>**<u>s Powers</u>**. No provision contained in this Agreement shall in any way terminate, modify or alter, or be construed or interpreted as terminating, modifying or altering any of the powers, rights or authority vested in the Committee or, to the extent delegated, in its delegate pursuant to the terms of the Plan or resolutions adopted in furtherance of the Plan, including, without limitation, the right to make certain determinations and elections with respect to the Stock Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **<u>Binding Effect</u>**. This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **<u>Amendment or Termination</u>**. The Employee and the Company may amend this Agreement in writing to the extent permitted under the terms of the Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Stock Units in this Agreement does not create any contractual right or other right to receive any Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Employee's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **<u>Governing Law</u>**. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Employee on account of non-compliance with Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **<u>Execution</u>**. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and same instrument. Execution by the Employee is an acceptance and acknowledgement of receipt of a copy of the Plan and this Agreement. Employee further acknowledges that he has been advised to consult his own tax advisor regarding the tax consequences of the vesting or settlement of the Stock Units or a disposition of the underlying shares.

*[Signature Page Follows]*

**IN WITNESS WHEREOF**, the Company has caused this Agreement to be duly executed by a duly authorized officer, and Employee has executed this Agreement, all as of the Grant Date set forth herein.

**EMPLOYEE: COMPANY:**

**LIGHPATH TECHNOLOGIES, INC.,**

a Delaware corporation

____________________________________ ____________________________________

Signature Signature

____________________________________ ____________________________________

Name Name

____________________________________ ____________________________________

Title (if executed by a representative of the Title

Employee)

## Exhibit 10.3

Exhibit 10.3

**<u>LIGHTPATH TECHNOLOGIES, INC.</u>**

**<u>2018 STOCK AND INCENTIVE COMPENSATION PLAN (</u>**<u>"</u>**<u>PLAN</u>**<u>"</u>**<u>)</u>**

**<u>Stock Option Award Agreement</u>**

This STOCK OPTION AWARD AGREEMENT (the "Agreement") is entered into as of the Grant Date specified in Section A by and between LIGHTPATH TECHNOLOGIES, INC., a Delaware corporation (the "Company"), and the UNDERSIGNED OPTIONEE ("Optionee"). Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. <u>NOTICE OF STOCK OPTION GRANT</u>**

Optionee: [Name]

The Optionee has been granted an Option to purchase Common Shares of the Company, subject to the terms and conditions of the Plan and this Agreement, as follows:

---

| | |
|:---|:---|
| Grant Date | March 23, 2026 |
| Exercise Price per Share | $10.53 |
| Total Number of Shares | [NUMBER OF SHARES] |
| Type of Option [*choose one*] | ___ Incentive Stock Option<br> _<u>X</u>_ Nonqualified Stock Option |
| Expiration Date | March 23, 2036 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. <u>TERMS OF OPTION</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Vesting.</u> Subject to accelerated vesting as may be set forth in the Plan or otherwise be determined by the Company, this Option will be exercisable, in whole or in part, in accordance with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Shares covered by this Option shall vest based upon the satisfaction of the annual revenue and adjusted EBITDA growth targets below over the [__]-year performance period following the Grant Date. For the avoidance of doubt, the satisfaction of a tier of revenue and adjusted EBITDA growth targets shall result in the vesting of all Shares covered by this Option up through and including the performance tier that was satisfied.

---

| | | |
|:---|:---|:---|
| Revenue Target | Adjusted EBITDA Growth Target | Aggregate Vested Shares |
| $[___] | [__]% | [__] |
| $[___] | [__]% | [__] |
| $[___] | [__]% | [__] |
| [$[___] | [__]% | [__]] |

---

For purposes of this Agreement, the Company's gross revenue shall be taken into account, excluding any increases in revenue that relate solely to an increase in the Company's revenue on account of the "Base Revenue" (as defined below) attributable to an entity that is acquired by the Company and whose revenue is consolidated into the Company's financial statements from the date of acquisition. Notwithstanding the last sentence, additional revenue generated by the acquired entity following the date of acquisition in excess of its Base Revenue shall be taken into account for purposes of the revenue targets under this Agreement. For example, if the Company completes an acquisition of an entity with Base Revenue of $22,000,000 and post-acquisition aggregate revenue of $30,000,000 in the first year following acquisition and $40,000,000 in the second year following acquisition, $8,000,000 and $12,000,000, respectively, of such revenue shall be taken into account for purposes of the vesting requirements set forth herein. For purposes of this Agreement, the term "Base Revenue" shall mean the gross revenue generated by the acquired entity over the 12-month period immediately preceding the effective date of its acquisition by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [RESERVED]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Exercise of Option.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Right to Exercise</u>. This Option shall be exercisable during its term in accordance with the applicable provisions of the Plan and this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Method of Exercise</u>. This Option shall be exercisable by delivery of an exercise notice (the "Exercise Notice"), in the form provided by the Company, which shall state (i) the Optionee's election to exercise the Option; (ii) the number of Shares with respect to which the Option is being exercised; and (iii) such other representations and agreements as may be required by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all exercised shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Method of Payment</u>. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee, subject to approval by the Administrator:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) cash or check;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) surrender of other Shares that, (A) in the case of Shares acquired from the Company, either directly or indirectly, have been owned by the Optionee, and not subject to a substantial risk of forfeiture, for more than six (6) months on the date of surrender, and (B) have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the exercised Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) delivery of an irrevocable and unconditional undertaking by a creditworthy broker (or written instructions from the Optionee to such a broker) to deliver promptly to the Company sufficient funds to pay the aggregate Exercise Price and any required tax withholding; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) delivery of such other lawful consideration as the Administrator may permit in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Issuance of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) No Shares shall be issued pursuant to the exercise of an Option unless (i) such issuance and such exercise comply with Applicable Law; and (ii) to the extent requested by the Company, the Optionee enters into, executes, and delivers any and all buy-sell, purchase option, shareholder, and other agreements regarding the disposition of the Shares held by the Optionee and the purchase of such Shares by the Company, as the Company shall determine to be necessary or appropriate in its sole discretion. Assuming compliance with the forgoing the Shares shall be considered transferred to the Optionee for income tax purposes on the date on which the Option is exercised with respect to such Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Each exercise of this Option shall, at the election of the Administrator, be contingent upon receipt by the Company from the holder of this Option of such written representations concerning his or her intentions with regard to retention or disposition of the Shares being acquired by exercise of this Option and/or such written covenants and agreements as to the manner of disposal of such Shares as, in the opinion of the Company, may be necessary to ensure that any disposition by such holder will not involve a violation of the Securities Act or any similar or superseding statute or statutes, or any other applicable statute or regulation, as then in effect. This Option shall be subject to the requirement that if at any time the Company shall determine, in its discretion, that the listing, registration or qualification of the Shares subject to this Option upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of the issuance or delivery of Shares hereunder, this Option may not be exercised unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Exercise Period</u>. In no event may the Optionee exercise this Option after the Expiration Date. Notwithstanding anything to the contrary in the Plan, and subject to the vesting restrictions set forth in Section B.1 of this Agreement, this Option shall be exercisable for ten (10) years following the Grant Date. Notwithstanding the last sentence, upon the Optionee's Termination of Employment, the Option, to the extent then vested, must be exercised within the period set forth under Section 13(c) of the Plan, as applicable. In the event the Option is a Nonqualified Stock Option, the Administrator may extend the otherwise applicable exercise period to a date that is not later than the Expiration Date to the extent such extension is permitted by Applicable Law and does not result in the Option being treated as a new Award under the Plan. Any portion of this Option that remains unexercised at the end of the applicable exercise period shall be forfeited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C. <u>AGREEMENT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Option</u>. Pursuant to the Plan, the Company hereby grants to the Optionee, an Option to purchase, from the Company, for the Exercise Price set forth above, Common Shares of the Company. This Option is subject to the terms and conditions of the Plan, which are incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Agreement, the terms and conditions of the Plan shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Type of Option</u>. If designated in Part I as an Incentive Stock Option, this Option is intended to qualify as an Incentive Stock Option as defined in Code Section 422. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall be treated as a Nonqualified Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Restrictions on Exercise</u>. This Option may not be exercised if the issuance of such Shares upon such exercise or the method of payment of consideration for such Shares would constitute a violation of any Applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Rights as Shareholder</u>. Neither the Optionee nor his or her guardian or legal representatives shall be a shareholder of the Company or have any of the rights or privileges of a shareholder of the Company in respect of any of the Shares deliverable upon the exercise of this Option unless and until certificates representing such Shares shall have been issued and delivered to the Optionee or his or her guardian or legal representative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Non-Transferability of Option</u>. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of the Optionee only by the Optionee. The terms of the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors, and assigns of the Optionee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Term of Option</u>. This Option may be exercised only within the term set out in the Notice of Stock Option Grant and may be exercised during such term only in accordance with the Plan and the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Tax Obligations</u>. The Optionee agrees to make appropriate arrangements with the Company (or the Affiliate employing or retaining the Optionee) for the satisfaction of all federal, state, local, and foreign income and employment tax withholding requirements applicable to the Option exercise. The Optionee acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Entire Agreement; Governing Law</u>. The Plan is incorporated herein by reference. The Plan and this Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Optionee with respect to the subject matter hereof, and, except as provided under the Plan, may not be modified adversely to the Optionee's interest except by means of a writing signed by the Company and the Optionee. This Agreement is governed by the internal substantive laws but not the choice of law rules of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>No Guarantee of Continued Service</u>. THE OPTIONEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREUNDER DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS AN EMPLOYEE OR SERVICE PROVIDER FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH THE OPTIONEE'S RIGHT OR THE COMPANY'S RIGHT TO TERMINATE THE OPTIONEE'S RELATIONSHIP AS AN EMPLOYEE OR SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.

The Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Optionee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan and this Agreement. The Optionee hereby agrees to accept, as binding, conclusive, and final, all decisions or interpretations of the Company upon any questions arising under the Plan or this Agreement. The Optionee further agrees to notify the Company upon any change in the residence address indicated herein.

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by an officer thereunto duly authorized, and the Optionee has executed this Agreement, all as of the Date of Grant.

LIGHPATH TECHNOLOGIES, INC., a Delaware corporation

By: _______________________________________

Name:

Title:

OPTIONEE

By: ________________________________________

Name: [NAME]

## Exhibit 31.1

Exhibit 31.1

**Certification of Chief Executive Officer**

**Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934**

I, Shmuel Rubin, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LightPath Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: <u>May 7, 2026</u>  | /s/ Shmuel Rubin  |
|  | Shmuel Rubin |
|  | President and Chief Executive Officer |

---

## Exhibit 31.2

Exhibit 31.2

**Certification of Chief Financial Officer**

**Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934**

I, Albert Miranda, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of LightPath Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: <u>May 7, 2026</u> | /s/ Albert Miranda |
|  | Albert Miranda |
|  | Chief Financial Officer |

---

## Exhibit 32.1

Exhibit 32.1

**Certification of Chief Executive Officer**

**Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: <u>May 7, 2026</u> | /s/ Shmuel Rubin  |
|  | Shmuel Rubin |
|  | President and Chief Executive Officer |

---

The certifications set forth above are being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to LightPath Technologies, Inc. and will be retained by LightPath Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

## Exhibit 32.2

Exhibit 32.2

**Certification of Chief Financial Officer**

**Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: <u>May 7, 2026</u> | /s/ Albert Miranda  |
|  | Albert Miranda |
|  | Chief Financial Officer |

---

The certifications set forth above are being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to LightPath Technologies, Inc. and will be retained by LightPath Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.